---

UNITED STATES SECURITIES
AND EXCHANGE COMMISSION

WASHINGTON,
D.C. 20549

| |  | 
| |  | 
| |  | 

FORM 10-Q

Quarterly
Report Under Section 13 or 15(d) 
of the 
Securities Act of 1934

FOR QUARTER ENDED MARCH 31, 2008 
Commission File Number 0-12248

DAXOR CORPORATION(Exact Name as Specified in its Charter)

|                                                                |  |                                     
|--------------------------------------------------------------- |  | ------------------------------------
|New York                                                        |  | 13-2682108                          
|(State or
 Other Jurisdiction of Incorporation or Organization) |  | (I.R.S. Employer Identification No.)
|                                                                |  |                                     
|                                                               
|350 Fifth Ave                                                  
|Suite 7120                                                     
|New York, New York 10118                                       
|(Address of Principal Executive Offices & Zip Code)            
|                                                               

|                               |  |                
|------------------------------ |  | ---------------
|Registrants Telephone Number: |  | (212)
 244-0555
|(Including Area Code)          |  |                

Indicate
by check mark whether the registrant (1) has filed all reports required by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements for the
past 90 days.

|                
|----------------
|Yes   x    No  o

Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, or a non-accelerated filer. See definition of accelerated
filer and large accelerated filer in Rule 12-b-2 of the Exchange Act:

|                          |                      |                        
|------------------------- | -------------------- | -----------------------
|Large Accelerated Filer o | Accelerated
 Filer o | Non-accelerated Filer x

Indicate
by check mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act).

|               
|---------------
|Yes   o   No  x

Indicate
the number of shares outstanding of each of the issuers classes of common
stock, as of the latest practicable date.

|                                        |                                         
|--------------------------------------- | ----------------------------------------
|CLASS                                   | 4,365,518
 OUTSTANDING AT April 30, 2008
|                                        |                                         
|COMMON STOCK
 PAR VALUE: $.01 per share |                                         

---



DAXOR CORPORATION AND SUBSIDIARY

TABLE OF CONTENTS

|                              |          |  |                                                                                                                   |       
|----------------------------- | -------- |  | ----------------------------------------------------------------------------------------------------------------- | ------
|PART I. FINANCIAL INFORMATION |         
|                              |          |  |                                                                                                                   |       
|                              | Item 1.  |  | FINANCIAL STATEMENTS (Unaudited)                                                                                  |       
|                              |          |  |                                                                                                                   |       
|                              |          |  | Index to Financial Statements                                                                                     | 1-2   
|                              |          |  |                                                                                                                   |       
|                              |          |  | Condensed Consolidated Balance Sheets at March 31, 2008 (Unaudited)
 and December 31, 2007 - (Audited)            | F-1   
|                              |          |  |                                                                                                                   |       
|                              |          |  | Condensed Consolidated Statements of Operations for the three months
 ended March 31, 2008 and 2007  (Unaudited) | F-2   
|                              |          |  |                                                                                                                   |       
|                              |          |  | Condensed Consolidated Statements of Cash Flows for the three months
 ended March 31, 2008 and 2007  (Unaudited) | F-3   
|                              |          |  |                                                                                                                   |       
|                              |          |  | Notes to Condensed Consolidated Financial Statements  (Unaudited)                                                | F-4-18
|                              |          |  |                                                                                                                   |       
|                              | Item 2.  |  | Managements Discussion and Analysis of Financial Condition and
 Results of Operations                            | 3-8   
|                              |          |  |                                                                                                                   |       
|                              | Item 3.  |  | Quantitative and Qualitative Disclosures about Market Risk                                                        | 9-11  
|                              |          |  |                                                                                                                   |       
|                              | Item 4.  |  | Controls and Procedures                                                                                           | 11    
|                              |          |  |                                                                                                                   |       
|                              | Item 5.  |  | Additional
 Information                                                                                           |       
|                              |          |  |                                                                                                                   |       
|PART II. OTHER INFORMATION    |         
|                              |          |  |                                                                                                                   |       
|                              | Item 1.  |  | Legal Proceedings                                                                                                 | 11    
|                              |          |  |                                                                                                                   |       
|                              | Item 1A. |  | Risk Factors                                                                                                      | 11    
|                              |          |  |                                                                                                                   |       
|                              | Item 2.  |  | Unregistered Sales of Equity Securities and Use of Proceeds                                                       | 11    
|                              |          |  |                                                                                                                   |       
|                              | Item 3.  |  | Defaults Upon Senior Securities                                                                                   | 11    
|                              |          |  |                                                                                                                   |       
|                              | Item 4.  |  | Submission of Matters to a Vote of Security Holders                                                               | 11    
|                              |          |  |                                                                                                                   |       
|                              | Item 5.  |  | Other Information                                                                                                 | 11    
|                              |          |  |                                                                                                                   |       
|                              | Item 6.  |  | Exhibits                                                                                                          | 12    

-1-

---



DAXOR CORPORATION AND SUBSIDIARY

|        |  |                                                                                                                   |       
|------- |  | ----------------------------------------------------------------------------------------------------------------- | ------
|PART I  |  | FINANCIAL INFORMATION                                                                                             |       
|        |  |                                                                                                                   |       
|Item 1. |  | Financial Statements (Unaudited)                                                                                  |       
|        |  |                                                                                                                   |       
|        |  | Index to Financial Statements                                                                                     |       
|        |  |                                                                                                                   |       
|        |  | Condensed Consolidated Balance Sheets at March 31, 2008 (Unaudited)
 and December 31, 2007 (Audited)              | F-1   
|       
|        |  | Condensed Consolidated Statements of Operations for the three months
 ended March 31, 2008 and 2007  (Unaudited) | F-2   
|        |  |                                                                                                                   |       
|        |  | Notes to Condensed Consolidated Financial Statements  (Unaudited)                                                | F-4-18

-2-

---



DAXOR CORPORATION AND SUBSIDIARY
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DAXOR CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS

|                                                                                                                                                                                           |  |                             |            |                              |   |             |  
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |  | --------------------------- | ---------- | ---------------------------- | - | ----------- | -
|                                                                                                                                                                                           |  | UNAUDITED
 March 31, 
 2008 |            | AUDITED
 December 31, 
 2007 |  
|                                                                                                                                                                                           |  |                             |            |                              |  
|ASSETS                                                                                                                                                                                     |  |                             |            |                              |   |             |  
|CURRENT ASSETS                                                                                                                                                                             |  |                             |            |                              |   |             |  
|Cash and cash equivalents                                                                                                                                                                  |  | $                           | 1,110,018  |                              | $ | 2,029,834   |  
|Receivable from broker (held in money
 market accounts)                                                                                                                                    |  |                             | 5,182,991  |                              |   | 10,495,417  |  
|Available-for-sale securities, at fair
 value                                                                                                                                              |  |                             | 69,600,036 |                              |   | 74,919,193  |  
|Securities sold, not received at fair value                                                                                                                                                |  |                             | 2,659,712  |                              |   | 12,404,409  |  
|Accounts receivable, net of allowance for
 doubtful accounts of $57,655 in 2008 and $57,655 in 2007                                                                                        |  |                             | 229,700    |                              |   | 214,334     |  
|Inventory                                                                                                                                                                                  |  |                             | 410,210    |                              |   | 255,834     |  
|Prepaid expenses and other current assets                                                                                                                                                  |  |                             | 118,929    |                              |   | 145,827     |  
|                                                                                                                                                                                           |  |                             |            |                              |   |             |  
|Total Current Assets                                                                                                                                                                       |  |                             | 79,311,596 |                              |   | 100,464,848 |  
|                                                                                                                                                                                           |  |                             |            |                              |   |             |  
|Property and equipment, net                                                                                                                                                                |  |                             | 2,121,837  |                              |   | 2,058,494   |  
|Other assets                                                                                                                                                                               |  |                             | 37,158     |                              |   | 37,158      |  
|                                                                                                                                                                                           |  |                             |            |                              |   |             |  
|                                                                                                                                                                                           |  |                             |            |                              |   |             |  
|Total Assets                                                                                                                                                                               |  | $                           | 81,470,591 |                              | $ | 102,560,500 |  
|                                                                                                                                                                                           |  |                             |            |                              |   |             |  
|                                                                                                                                                                                           |  |                             |            |                              |   |             |  
|LIABILITIES AND STOCKHOLDERS EQUITY                                                                                                                                                       |  |                             |            |                              |   |             |  
|                                                                                                                                                                                           |  |                             |            |                              |   |             |  
|CURRENT LIABILITIES                                                                                                                                                                        |  |                             |            |                              |   |             |  
|Accounts payable and accrued liabilities                                                                                                                                                   |  | $                           | 311,672    |                              | $ | 498,212     |  
|Loans payable                                                                                                                                                                              |  |                             | 2,592,418  |                              |   | 3,314,303   |  
|Income taxes payable                                                                                                                                                                       |  |                             |           |                              |   | 1,295,668   |  
|Mortgage payable, current portion                                                                                                                                                          |  |                             | 38,102     |                              |   | 37,313      |  
|Put and call options, at fair value                                                                                                                                                        |  |                             | 7,685,008  |                              |   | 5,972,632   |  
|Securities borrowed, at fair value                                                                                                                                                         |  |                             | 4,245,368  |                              |   | 20,362,259  |  
|Deferred revenue                                                                                                                                                                           |  |                             | 4,431      |                              |   | 7,417       |  
|Deferred income taxes                                                                                                                                                                      |  |                             | 11,853,505 |                              |   | 15,726,213  |  
|                                                                                                                                                                                           |  |                             |            |                              |   |             |  
|Total Current Liabilities                                                                                                                                                                  |  |                             | 26,730,504 |                              |   | 47,214,017  |  
|                                                                                                                                                                                           |  |                             |            |                              |   |             |  
|                                                                                                                                                                                           |  |                             |            |                              |   |             |  
|LONG TERM LIABILITIES                                                                                                                                                                      |  |                             |            |                              |   |             |  
|                                                                                                                                                                                           |  |                             |            |                              |   |             |  
|Mortgage payable, less current portion                                                                                                                                                     |  |                             | 420,696    |                              |   | 430,598     |  
|                                                                                                                                                                                           |  |                             |            |                              |   |             |  
|                                                                                                                                                                                           |  |                             |            |                              |   |             |  
|Total Liabilities                                                                                                                                                                          |  |                             | 27,151,200 |                              |   | 47,644,615  |  
|                                                                                                                                                                                           |  |                             |            |                              |   |             |  
|COMMITMENTS AND CONTINGENICES                                                                                                                                                              |  |                             |            |                              |   |             |  
|                                                                                                                                                                                           |  |                             |            |                              |   |             |  
|STOCKHOLDERS EQUITY                                                                                                                                                                       |  |                             |            |                              |   |             |  
|Common stock, $.01 par value, Authorized -
 10,000,000 shares Issued  5,316,550 shares Outstanding  4,402,818 and
 4,468,618 shares at March 31, 2008 and December 31, 2007,respectively |  |                             | 53,165     |                              |   | 53,165      |  
|Additional paid in capital                                                                                                                                                                 |  |                             | 10,612,016 |                              |   | 10,594,161  |  
|Accumulated other comprehensive income                                                                                                                                                     |  |                             | 22,013,651 |                              |   | 29,205,823  |  
|Retained earnings                                                                                                                                                                          |  |                             | 30,808,379 |                              |   | 23,487,371  |  
|Treasury stock, at cost, 913,732 and
 847,932 shares of Treasury stock at March 31, 2008 and December 31, 2007,
 respectively                                                              |  |                             | (9,167,820 | )                            |   | (8,424,635  | )
|                                                                                                                                                                                           |  |                             |            |                              |   |             |  
|Total Stockholders Equity                                                                                                                                                                 |  |                             | 54,319,391 |                              |   | 54,915,885  |  
|                                                                                                                                                                                           |  |                             |            |                              |   |             |  
|Total Liabilities and Stockholders Equity                                                                                                                                                 |  | $                           | 81,470,591 |                              | $ | 102,560,500 |  
|                                                                                                                                                                                           |  |                             |            |                              |   |             |  

See accompanying notes to
unaudited condensed consolidated financial statements.

F-1

---



DAXOR CORPORATION AND
SUBSIDIARYCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [UNAUDITED]
FOR THE THREE MONTHS ENDED

|                                                                             |  |                  |            |                  |   |            |  
|---------------------------------------------------------------------------- |  | ---------------- | ---------- | ---------------- | - | ---------- | -
|                                                                             |  | March 31,
  2008 |            | March 31,
  2007 |  
|                                                                             |  |                  |            |                  |  
|                                                                            
|REVENUES:                                                                    |  |                  |            |                  |   |            |  
|                                                                             |  |                  |            |                  |   |            |  
|Operating
  Revenues  equipment sales and related services                  |  | $                | 323,780    |                  | $ | 394,226    |  
|Operating
  Revenues  cryobanking and related services                      |  |                  | 97,133     |                  |   | 111,656    |  
|                                                                             |  |                  |            |                  |   |            |  
|                                                                             |  |                  |            |                  |   |            |  
|Total
  Revenues                                                             |  |                  | 420,913    |                  |   | 505,882    |  
|                                                                             |  |                  |            |                  |   |            |  
|Cost of
  Sales:                                                             |  |                  |            |                  |   |            |  
|                                                                             |  |                  |            |                  |   |            |  
|Cost of
  equipment sales and related services                               |  |                  | 138,614    |                  |   | 139,060    |  
|Cost of
  cryobanking and related services                                   |  |                  | 13,400     |                  |   | 12,475     |  
|                                                                             |  |                  |            |                  |   |            |  
|                                                                             |  |                  |            |                  |   |            |  
|Total Cost
  of Sales                                                        |  |                  | 152,014    |                  |   | 151,535    |  
|                                                                             |  |                  |            |                  |   |            |  
|                                                                             |  |                  |            |                  |   |            |  
|Gross Profit                                                                 |  |                  | 268,899    |                  |   | 354,347    |  
|                                                                             |  |                  |            |                  |   |            |  
|OPERATING
  EXPENSES:                                                        |  |                  |            |                  |   |            |  
|                                                                             |  |                  |            |                  |   |            |  
|Research and
  development expenses:                                         |  |                  |            |                  |   |            |  
|                                                                             |  |                  |            |                  |   |            |  
|Research and
  development-equipment sales and related services              |  |                  | 559,309    |                  |   | 548,190    |  
|Research and
  development-cryobanking and related services                  |  |                  | 48,242     |                  |   | 56,041     |  
|                                                                             |  |                  |            |                  |   |            |  
|                                                                             |  |                  |            |                  |   |            |  
|Total
  Research and Development Expenses                                    |  |                  | 607,551    |                  |   | 604,231    |  
|                                                                             |  |                  |            |                  |   |            |  
|                                                                             |  |                  |            |                  |   |            |  
|Selling,
  General & Administrative Expenses:                                |  |                  |            |                  |   |            |  
|                                                                             |  |                  |            |                  |   |            |  
|Selling,
  general, and administrative; equipment sales and related services |  |                  | 770,595    |                  |   | 754,780    |  
|Selling,
  general, and administrative; cryobanking and related services     |  |                  | 159,554    |                  |   | 201,203    |  
|                                                                             |  |                  |            |                  |   |            |  
|                                                                             |  |                  |            |                  |   |            |  
|Total
  Selling, General & Administrative Expenses                           |  |                  | 930,149    |                  |   | 955,983    |  
|                                                                             |  |                  |            |                  |   |            |  
|                                                                             |  |                  |            |                  |   |            |  
|Total
  Operating Expenses                                                   |  |                  | 1,537,700  |                  |   | 1,560,214  |  
|                                                                             |  |                  |            |                  |   |            |  
|                                                                             |  |                  |            |                  |   |            |  
|Loss from
  Operations                                                       |  |                  | (1,268,801 | )                |   | (1,205,867 | )
|                                                                             |  |                  |            |                  |   |            |  
|Other income
  (expenses):                                                   |  |                  |            |                  |   |            |  
|                                                                             |  |                  |            |                  |   |            |  
|Dividend
  income-investment portfolio                                       |  |                  | 630,782    |                  |   | 711,429    |  
|Realized
  gains on sale of securities, net                                  |  |                  | 5,830,999  |                  |   | 1,626,430  |  
|Mark to
  market of short positions                                          |  |                  | 2,176,041  |                  |   | 2,014,798  |  
|Other
  revenues                                                             |  |                  | 2,916      |                  |   | 2,755      |  
|Interest
  expense, net of interest income of $11,185 and $10,072            |  |                  | (29,515    | )                |   | (77,413    | )
|Administrative
  expense relating to portfolio investments                   |  |                  | (21,414    | )                |   | (12,138    | )
|                                                                             |  |                  |            |                  |   |            |  
|                                                                             |  |                  |            |                  |   |            |  
|Total Other
  Income, net                                                    |  |                  | 8,589,809  |                  |   | 4,265,861  |  
|                                                                             |  |                  |            |                  |   |            |  
|Income
  before income taxes                                                 |  | $                | 7,321,008  |                  | $ | 3,059,994  |  
|                                                                             |  |                  |            |                  |   |            |  
|Income tax
  expense                                                         |  |                  |           |                  |   |           |  
|                                                                             |  |                  |            |                  |   |            |  
|                                                                             |  |                  |            |                  |   |            |  
|Net income                                                                   |  | $                | 7,321,008  |                  | $ | 3,059,994  |  
|                                                                             |  |                  |            |                  |   |            |  
|                                                                             |  |                  |            |                  |   |            |  
|Weighted
  average number of shares outstanding- basic and diluted           |  |                  | 4,421,518  |                  |   | 4,606,787  |  
|                                                                             |  |                  |            |                  |   |            |  
|                                                                             |  |                  |            |                  |   |            |  
|Net income
  per common equivalent share - basic and diluted                 |  | $                | 1.66       |                  | $ | 0.66       |  
|                                                                             |  |                  |            |                  |   |            |  

See
accompanying notes to unaudited condensed consolidated financial statements.

F-2

---



DAXOR CORPORATION AND
SUBSIDIARYCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [UNAUDITED]
FOR THE THREE MONTHS ENDED

|                                                                                     |  |                  |             |                  |   |             |  
|------------------------------------------------------------------------------------ |  | ---------------- | ----------- | ---------------- | - | ----------- | -
|                                                                                     |  | March 31,
  2008 |             | March 31,
  2007 |  
|                                                                                     |  |                  |             |                  |  
|                                                                                    
|CASH FLOWS
  FROM OPERATING ACTIVITIES:                                              |  |                  |             |                  |   |             |  
|Net income                                                                           |  | $                | 7,321,008   |                  | $ | 3,059,994   |  
|                                                                                     |  |                  |             |                  |   |             |  
|                                                                                     |  |                  |             |                  |   |             |  
|Adjustment
  to reconcile net income(loss) to net cash used in operating activities: |  |                  |             |                  |   |             |  
|Depreciation                                                                         |  |                  | 68,659      |                  |   | 52,531      |  
|Non-cash compensation expense
associated
  with employee stock compensation plans    |  |                  | 17,855      |                  |   | 4,518       |  
|Gain on sale of fixed
assets                                                         |  |                  |            |                  |   | (102,449    | )
|Gains on sale of
investments                                                         |  |                  | (5,830,999  | )                |   | (1,626,430  | )
|Mark to market adjustments on
options &
  short sales                                |  |                  | (2,176,041  | )                |   | (2,014,798  | )
|                                                                                     |  |                  |             |                  |   |             |  
|Change in
  operating assets and liabilities:                                        |  |                  |             |                  |   |             |  
|Increase in accounts
receivable                                                      |  |                  | (15,366     | )                |   | (175,816    | )
|Decrease in prepaid expenses
& other
  current assets                                |  |                  | 26,898      |                  |   | 16,623      |  
|Increase in inventory                                                                |  |                  | (154,376    | )                |   | (38,063     | )
|Increase in other
assets                                                             |  |                  |            |                  |   | (2,050      | )
|Decrease in accounts payable
and accrued
  liabilities                               |  |                  | (186,540    | )                |   | (1,811      | )
|Decrease in income taxes
payable                                                     |  |                  | (1,295,668  | )                |   |            |  
|Decrease in deferred
revenue                                                         |  |                  | (2,986      | )                |   | (1,264      | )
|                                                                                     |  |                  |             |                  |   |             |  
|                                                                                     |  |                  |             |                  |   |             |  
|Net cash
  used in operating activities                                              |  |                  | (2,227,556  | )                |   | (829,015    | )
|                                                                                     |  |                  |             |                  |   |             |  
|                                                                                     |  |                  |             |                  |   |             |  
|CASH FLOWS
  FROM INVESTING ACTIVITIES:                                              |  |                  |             |                  |   |             |  
|Purchase of
  property and equipment                                                 |  |                  | (132,002    | )                |   | (891,842    | )
|Proceeds
  from sale of fixed assets                                                 |  |                  |            |                  |   | 130,500     |  
|Decrease in
  securities sold, not received at fair market value                     |  |                  | 9,744,697   |                  |   | 1,157,212   |  
|Decrease in
  securities borrowed, at fair market value                              |  |                  | (16,116,891 | )                |   | (1,871,927  | )
|Purchases of
  put and call options                                                  |  |                  | (28,607     | )                |   | (245        | )
|Sales of put
  and call options                                                      |  |                  | 8,434,122   |                  |   | 3,096,982   |  
|Acquisition
  of available for sale securities                                       |  |                  | (14,983,059 | )                |   | (7,827,157  | )
|Proceeds
  from sale of available for sale securities                                |  |                  | 10,551,237  |                  |   | 7,986,923   |  
|                                                                                     |  |                  |             |                  |   |             |  
|Net cash
  (used in) provided by investing activities                                |  |                  | (2,530,503  | )                |   | 1,780,446   |  
|                                                                                     |  |                  |             |                  |   |             |  
|                                                                                     |  |                  |             |                  |   |             |  
|CASH FLOWS
  FROM FINANCING ACTIVITIES:                                              |  |                  |             |                  |   |             |  
|Proceeds
  from margin payable                                                       |  |                  | 17,308,753  |                  |   | 10,924,756  |  
|Repayment of
  margin payable                                                        |  |                  | (12,618,212 | )                |   | (14,972,469 | )
|Repayment of
  bank loan                                                             |  |                  | (100,000    | )                |   |            |  
|Purchase of
  treasury stock                                                         |  |                  | (743,185    | )                |   | (158,090    | )
|Proceeds
  from mortgage payable                                                     |  |                  |            |                  |   | 500,000     |  
|Repayment of
  mortgage payable                                                      |  |                  | (9,113      | )                |   | (5,930      | )
|                                                                                     |  |                  |             |                  |   |             |  
|                                                                                     |  |                  |             |                  |   |             |  
|Net cash
  provided by (used in) financing activities                                |  |                  | 3,838,243   |                  |   | (3,711,733  | )
|                                                                                     |  |                  |             |                  |   |             |  
|                                                                                     |  |                  |             |                  |   |             |  
|Net decrease
  in cash and cash equivalents                                          |  |                  | (919,816    | )                |   | (2,760,302  | )
|Cash and
  cash equivalents at beginning of period                                   |  |                  | 2,029,834   |                  |   | 2,838,927   |  
|                                                                                     |  |                  |             |                  |   |             |  
|                                                                                     |  |                  |             |                  |   |             |  
|Cash and
  cash equivalents at end of period                                         |  | $                | 1,110,018   |                  | $ | 78,625      |  
|                                                                                     |  |                  |             |                  |   |             |  
|                                                                                     |  |                  |             |                  |   |             |  
|Supplemental
  Disclosures of Cash Flow Information:                                 |  |                  |             |                  |   |             |  
|Cash paid
  during the quarter for:                                                  |  |                  |             |                  |   |             |  
|Interest                                                                             |  | $                | 40,699      |                  | $ | 87,484      |  
|Income taxes                                                                         |  | $                | 1,302,210   |                  | $ |            |  

See
accompanying notes to unaudited condensed consolidated financial statements.

F-3

---



DAXOR CORPORATION AND SUBSIDIARYNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 
March 31, 2008 and 2007 (Continued) 
(Unaudited)

(1) BUSINESS
AND SIGNIFICANT ACCOUNTING POLICIES

BUSINESS

Daxor
Corporation is a medical device manufacturing company that offers additional
biotech services, such as cryobanking, through its wholly owned subsidiary,
Scientific Medical Systems Corp. The Company provides long-term frozen blood
and semen storage services to enable individuals to store their own blood and
semen. The main focus of Daxor Corporation has been the development of an
instrument that rapidly and accurately measures human blood volume. This
instrument is used in conjunction with a single use diagnostic injection and
collection kit.

SIGNIFICANT
ACCOUNTING POLICIES

Basis of Presentation

The
accompanying unaudited condensed consolidated financial statements reflect all
adjustments of a normal recurring nature, which are, in the opinion of
management, necessary for a fair statement of the financial position and
results of operations for the interim periods presented. The condensed
consolidated financial statements are unaudited and are subject to such
year-end adjustments as may be considered appropriate and should be read in
conjunction with the historical consolidated financial statements of Daxor
Corporation for the years ended December 31, 2007, 2006 and 2005, included in
Daxor Corporations Annual Report on Form 10-K for the fiscal year ended
December 31, 2007. The December 31, 2007 condensed consolidated balance sheet
data was derived from audited financial statements but does not include all
disclosures required by accounting principles generally accepted in the United
States of America. Operating results for the three month period ended March 31,
2008 are not necessarily indicative of the results that may be expected for the
year December 31, 2008.

These
condensed consolidated financial statements have been prepared in accordance
with US GAAP and under the same accounting principles as the consolidated
financial statements included in the Annual Report on Form 10-K. Certain
information and footnote disclosures related thereto normally included in the
financial statements prepared in accordance with US GAAP have been omitted in
accordance with Rule 10-01 of Regulation S-X.

Principles of Consolidation

The
condensed consolidated financial statements include the accounts of Daxor
Corporation and Scientific Medical Systems Corp, a wholly-owned subsidiary. All
inter-company transactions and balances have been eliminated in consolidation.

Segment Reporting

The
Company has two operating segments: Equipment Sales and Related Services, and
Cryobanking and Related Services.

The
Equipment Sales and Related Services segment comprises the Blood Volume
Analyzer equipment and related activity. This includes equipment sales,
equipment rentals, equipment delivery fees, BVA-100 kit sales and service
contract revenues.

The
Cryobanking and Related Services segment is comprised of activity relating to
the storage of blood and semen, and related laboratory services and handling
fees.

Although
not deemed an operating segment, the Company reports a third business segment;
Investment activity. This segment reports the activity of the Companys
investment portfolio. This includes all earnings, gains and losses, and
expenses relating to these investments.

Use of Estimates

In
order to prepare financial statements that conform to the requirements of US
GAAP, management makes estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and
liabilities as of the dates of the financial statements and the results of
operations during the reporting periods. Actual results may differ from these
estimates.

Reclassifications

Reclassifications occurred to certain prior year
amounts in order to conform to the current year classifications. The
reclassifications have no effect on the reported net income.

F-4

---



DAXOR CORPORATION AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 
March 31, 2008 and 2007 (Continued) 
(Unaudited)

Cash and Cash Equivalents

Cash
and cash equivalents include time deposits and short term investments with
original maturities of three months or less. Normally, these short term
investments consist of U.S. Treasury Bills. At March 31, 2008 and March 31,
2007 there were $980,946 and $0 worth of short term investments respectively included
as cash equivalents.

Fair Value of Financial Instruments

The
carrying amounts of financial instruments, including cash and cash equivalents,
accounts receivable and payable, accrued liabilities deferred option premiums
and short term debt (loans payable and short positions on securities)
approximate fair value because of their short maturities. The carrying amount
of the mortgage payable is estimated to approximate fair value as the mortgage
was closed in 2007 at a current interest rate.

F-5

---



DAXOR CORPORATION AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 
March 31, 2008 and 2007 (Continued) 
(Unaudited)

Available-for-Sale Securities

Available-for-sale
securities represent investments in debt and equity securities (primarily
common and preferred stock of electric utility companies) that management has
determined meet the definition of available-for-sale under SFAS No. 115 - Accounting for Certain Investments in Debt and Equity
Securities. Accordingly, these investments are stated at fair market
value and all unrealized holding gains or losses are recorded in the
Stockholders Equity section as Accumulated Other Comprehensive Income (Loss).
Conversely, all realized gains, losses and earnings are recorded in the
Statement of Operations under Other Income (Expense).

At
certain times, the Company will engage in short selling of stock. When this
occurs, the short position is marked to the market and recorded as a realized
sale. Any gain or (loss) is recorded for the period presented.

Historical
cost is used by the Company to determine all gains and losses, and fair market
value is obtained by readily available market quotes on all securities.

Put and Call Options at fair value

As
part of the companys investment strategy, put and call options are sold on
various stocks the company is willing to buy or sell. The premiums received are
deferred until such time as they are exercised or expire. In accordance with
SFAS No. 133 - Accounting for Derivative
Instruments and Hedging Activities,these options are marked to
market for each reporting period using readily available market quotes, and
this fair value adjustment is recorded as a gain or loss in the Statement of
Operations.

Upon
exercise, the value of the premium will adjust the basis of the underlying
security bought or sold. Options that expire are recorded as income in the
period they expire.

Receivable from Broker

The
Receivable from Broker represents cash proceeds from sales of securities and
dividends. These proceeds are kept in dividend bearing money market accounts.

Securities borrowed at fair value

When
a call option that has been sold short is exercised, this creates a short
position in the related common stock. The recorded cost of these short
positions is the amount received on the sale of the stock plus the proceeds
received from the underlying call option. These positions are shown on the
Balance Sheet as Securities borrowed at fair value and the carrying value is
reduced or increased at the end of each quarter by the mark to market
adjustment which is recorded in accordance with SFAS No. 115  Accounting for
Certain Investments in Debt and Equity Securities.

Securities sold, not yet received at fair
value

Some
of the financial institutions who hold our securities do not increase our
account with the cash proceeds on the sale of a short stock. In lieu of cash,
our account receives a credit for the proceeds of the short sale. Cash is added
to or subtracted from our account weekly based on the market value of our short
positions. These securities are recorded by the Company as received but not
delivered and are valued at their quoted market price.

Investment Goals, Strategies and Policies

The
Companys investment goals are capital preservation and maintaining returns on
capital with a high degree of safety. These goals are accomplished through the
following strategies and policies:

| |    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
| | -- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| | 1. | The Company
  maintains a diversified securities portfolio comprised primarily of dividend
  bearing electric utility common and preferred stocks. The Company also sells
  covered calls on portions of its portfolio and also sells puts on stocks it
  is willing to own. It also sells uncovered calls and will periodically have
  short positions of up to 15% of the value of its portfolio. The Companys
  short position may temporarily rise to 20% of the Companys portfolio without
  any specific action because of changes in valuation, but should not exceed
  this amount. The Companys investment policy is to maintain a minimum of 85%
  of its portfolio in electric utilities. Investments in utilities are
  primarily in electric companies. Investments in non-utility stocks will not
  exceed 15% of the portfolio.

F-6

---



DAXOR CORPORATION AND SUBSIDIARY 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 
March 31, 2008 and 2007 (Continued) 
(Unaudited)

| |    |                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
| | -- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| | 2. | Investment
  in speculative issues, including short sales, maximum of 15%.                                                                                                                   
| |    |                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
| | 3. | Limited use
  of options to increase yearly investment income.                                                                                                                               
| |    |                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
| |    | a.                                                                                                                                                                                            | The use of
Call Options. Covered options can be sold up to a maximum of 20% of the
value of the portfolio. This provides extra income in addition to dividends
received from the companys investments. The risk of this strategy is that
investments which the company may have preferred to retain can be called
away. Therefore, a limitation of 20% is placed on the amount of stock on
which options can be written. The amount of the portfolio on which options are
actually written is usually between 3-10% of the portfolio. The historical
turnover of the portfolio is such that the average holding period is in
excess of five years for available for sale securities.                                                                                                                                                                                                                                                                                                                          
| |    |                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
| |    | b.                                                                                                                                                                                            | The use of
Put options. Put options are written on stocks
which the company is willing to purchase. While the company does not have a
high rate of turnover in its portfolio, there is some turnover; for example,
due to preferred stocks being called back by the issuing company, or stocks
being called away because call options have been written. If the stock does
not go below the put exercise price, the company records the proceeds from
the sale as income. If the put is exercised, the cost basis is reduced by the
proceeds received from the sale of the put option. There may be occasions
where the cost basis of the stock is lower than the market price at the time
the option is exercised.                                                                                                                                                                                                                                                                                            
| |    |                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
| |    | c.                                                                                                                                                                                            | Speculative
  Short Sales/Short Options. The company normally
  limits its speculative transactions to no more than 15% of the value of the
  portfolio. The company may sell uncovered calls on certain stocks. If the
  stock price does not rise to the price of the calls, the option is not
  exercised, and the company records the proceeds from the sale of the call as income.
  If the call is exercised, the company will have a short position in the
  related stock. The company then has the choice of covering the short position
  or selling a put against it. If the put is exercised, the short position is
  covered. The companys current accounting policy is to mark to the market at
  the end of each quarter any short positions, and include it in the income
  statement. While the company may have so-called speculative positions equal
  to 15% of its accounts, in actual practice the short stock positions usually
  account for less than 10% of the assets of the company.
| |    |                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
| | 4. | In the event
  of a merger, the Company will elect to receive shares in the new company. In
  the event of a cash only offer, the Company will receive cash and be forced
  to sell it stock.

Accounts Receivable

Accounts
receivable are reviewed by the Company at the end of each reporting period to
determine the collectability based upon the aging of the balances and the
history of the customer. As of March 31, 2008, the Company determined that a
reserve of $57,655 should be placed against the outstanding receivable balance
of $287,355. As of December 31, 2007, the Company determined that a reserve of
$57,655 should be placed against the outstanding receivable balance of $271,989.

Inventory

Inventory is
stated at the lower of cost or market, using the first-in, first-out method
(FIFO), and consists primarily of finished goods.

Prepaid Expenses and Other Current Assets

Prepaid
expenses and other current assets generally consist of prepayments for future
services and corporate capital base/personal holding taxes. Prepayments are
expensed when the services are received or as the prepaid capital base/personal
holding taxes are offset by the related tax liability. All prepaid expenses and
taxes are expensed within one year of the Balance Sheet date and are thus
classified as Current Assets.

Property and Equipment

Property and
Equipment is stated at cost and consists of BVA equipment loaned on a trial
basis, laboratory and office equipment, furniture and fixtures, and leasehold
improvements. These assets are depreciated under the straight-line method, over
their estimated useful lives, which range from 5 to 39 years.

F-7

---



DAXOR CORPORATION AND SUBSIDIARY 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 
March 31, 2008 and 2007 (Continued) 
(Unaudited)

Amounts spent
to repair or maintain these assets arising out of the normal course of business
are expensed in the period incurred. The cost of betterments and additions are
capitalized and depreciated over the life of the asset. The cost of assets
disposed of or determined to be non-revenue producing, together with the
related accumulated depreciation applicable thereto, are eliminated from the
accounts, and any gain or loss is recognized.

In accordance
with SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived
Assets, management reviews long-lived assets for impairment whenever events or
changes in circumstances indicate that the carrying amount of an asset may not
be recoverable. Currently, management does not believe there is any impairment
of any long-lived assets.

Revenue Recognition

The
Company recognizes operational revenues from several sources. The first source
is the sale of equipment, the Blood Volume Analyzer, to customers. The second
source is the sale and associated shipping revenues of single-use radioactive
doses (Volumex) that are injected into the patient and measured by the Blood
Volume Analyzer. The third source of revenue is service contracts on the Blood
Volume Analyzer, after it has been sold to a customer. The fourth source of
revenue is the storage fees associated with cryobanked blood and semen
specimens. The fifth is lab revenues from laboratory services, and the sixth is
revenue from donor semen sales.

The
Company currently offers three different methods of purchasing the Blood Volume
Analyzer equipment. A customer may purchase the equipment directly, lease the
equipment, or rent the equipment on a month-to-month basis. The revenues
generated by a direct sale or a monthly rental are recognized as revenue in the
period in which the sale or rental occurs. If a customer selects the lease
option, the Company refers the customer to a third party leasing company with
whom it has established a relationship. If the lease is approved by the
independent leasing company, the Company receives 100% of the sales proceeds
from the leasing company and recognizes 100% of the revenue. The leasing
company then deals directly with the customer with regard to lease payments and
any related collections.

The
sales of the single-use radioactive doses (Volumex) that are used in
conjunction with the Blood Volume Analyzer are recognized as revenue in the
period in which the sale occurs.

The
storage fees associated with the cryobanked blood and semen samples are
recognized as income in the period for which the fee applies. Although the
Company historically offered annual storage fee contracts, effective October 1,
2005, the Company only offers storage term contracts of three months or less.

Income Taxes

The
Company accounts for income taxes under the provisions of SFAS No. 109 - Accounting for Income Taxes. This
pronouncement requires recognition of deferred tax assets and liabilities for
the estimated future tax consequences of events attributable to differences
between the amounts of existing assets and liabilities and their respective tax
bases and operating loss and tax credit carry forwards. Deferred tax assets and
liabilities are measured using tax rates in effect for the year in which the
differences are expected to be recovered or settled. The effect on deferred tax
assets and liabilities of changes in tax rates is recognized in the statement
of operations in the period in which the enactment rate changes. Deferred tax
assets and liabilities are reduced through the establishment of a valuation
allowance at such time as, based on available evidence, it is more likely than
not that the deferred tax assets will not be realized.

Comprehensive Income (Loss)

The
Company reports components of comprehensive income under the requirements of
SFAS No. 130 - Reporting Comprehensive
Income. This statement establishes rules for the reporting of
comprehensive income and requires certain transactions to be presented as
separate components of stockholders equity. The Company currently reports the
unrealized holding gains and losses on available-for-sale securities, net of
deferred taxes, as accumulated other comprehensive income (loss).

Product Warrantees and Related Liabilities

When
a Blood Volume Analyzer has been sold to a customer, the Company offers a one
year warranty on the product, which covers all mechanical failures. This one
year warranty is effective on the date of sale of the unit. All major
components of the equipment are purchased and warranted by the original third
party manufacturers. After the one year period expires, customers may purchase
a service contract through the Company, which is usually offered in one-year
increments. To date, the Company has not experienced any major mechanical
failures on any equipment sold. In addition, the majority of the potential
liability would revert to the original manufacturer. Due to this history, a
liability has not been recorded with respect to product or warranty liability.

F-8

---



DAXOR CORPORATION AND SUBSIDIARY 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 
March 31, 2008 and 2007 (Continued) 
(Unaudited)

Historically,
service contracts were recorded by the Company as deferred revenue and were
amortized into income in the period in which they were earned. Effective
January 1, 2006, the company offers service contracts priced on annual basis
which are billed quarterly and revenue is earned in the same calendar quarter
that it is billed. As at March 31, 2008 and December 31, 2007, deferred revenue
pertaining to the historical service contracts was $4,229 and $7,417 respectively.

Advertising Costs

Advertising
expenditures relating to the advertising and marketing of the Companys
products and services are expensed in the period incurred. Advertising Expenses
for the quarters ended March 31, 2008 and 2007 amounted to $ 3,516 and $ 3,496.

Earnings Per Share

The Company
computes earnings per share in accordance with SFAS No. 128, Earnings per
Share. Basic earnings per common share is computed by dividing income or loss
available to common stockholders by the weighted average number of common
shares outstanding for the period. Diluted earnings per common share are based
on the average number of common shares outstanding during each period, adjusted
for the effects of outstanding stock options.

For the
quarters ended March 31, 2008 and 2007, stock options were not included in the
computation of diluted loss per common share due to their anti-dilutive effect.
The number of anti-dilutive stock options excluded from the computation of
diluted loss per common share was 110,500 and 91,900, respectively.

Leased Employees

The Company
has entered into an agreement with ADP Total Source, whereby the Company leases
its employees from ADP. The agreement requires the Company to reimburse ADP for
all employee wages, related taxes, employee benefit costs and human resource
fees.

The Company
records these payments using the same classifications for which the
reimbursement is made (i.e. wage reimbursements are recorded as wage expense).

Stock Based Compensation

In
December 2004, the FASB issued SFAS No. 123R - Share-Based
Payment: An Amendment of FASB Statements No. 123, (SFAS 123R)
which requires companies to recognize in the income statement the grant-date
fair value of stock options and other equity-based compensation issued to employees.
SFAS 123R is effective for financial statements issued for annual reporting
periods that begin after June 15, 2005. In adopting SFAS No. 123R, the Company
used the modified prospective transition method, as of January 1, 2006, the
first day of the Companys fiscal year 2006.

Under
the modified prospective transition method, awards that are granted, modified
or settled after the date of adoption will be measured and accounted for in
accordance with SFAS 123R. Compensation cost for awards granted prior to, but
not vested, as of the date SFAS 123R is adopted would be based on the grant
date attributes originally used to value those awards for pro forma purposes
under SFAS 123. The Companys condensed consolidated financial statements as of
and for the three months ended March 31, 2008, reflect the impact of SFAS No.
123R. In accordance with the modified prospective transition method, the
Companys consolidated financial statements for periods prior to January 1,
2006 have not been restated to reflect, and do not include, the impact of SFAS
123R.

SFAS
123R also requires the tax benefits associated with these share-based payments
to be classified as financing activities in the Condensed Consolidated
Statements of Cash Flows, rather than as operating cash flows as required under
previous regulations.

At
March 31, 2008, the Company has one stock-based compensation plan, the 2004
Stock Option Plan. This Plan allows for the issuance of a maximum of 200,000
shares of common stock or 5% of the outstanding balance of shares of the
Company on the date of grant, whichever is greater. Under the provisions of the
Option Plan, the exercise price of any stock options issued is a minimum of
110% of the closing market price of the Companys stock on the grant date of
the option.

F-9

---



DAXOR CORPORATION AND SUBSIDIARY 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 
March 31, 2008 and 2007 (Continued) 
(Unaudited)

At
March 31, 2008, there is a total unvested stock-based compensation expense of $
51,945 and a total weighted average remaining term of 0.71 years. Total
share-based compensation expense recognized in the Statement of Operations
aggregated $17,855 for the three months ended March 31, 2008 and $4,518 for the
three months ended March 31, 2007.

To
calculate the option-based compensation under SFAS 123R, the Company used the
Black-Scholes option-pricing model, which it had previously used for the
valuation of option-based awards for its pro-forma information required under
SFAS 123 for periods prior to fiscal 2006. The Companys determination of fair
value of option-based awards on the date of grant using the Black-Scholes model
is affected by the Companys stock price as well as assumptions regarding a
number of subjective variables. These variables include, but are not limited
to, the Companys expected stock price volatility over the term of the awards,
risk-free interest rate, and the expected life of the options. The risk-free
interest rate is based on a treasury instrument whose term is consistent with
the expected life of the stock options. The expected volatility, holding
period, and forfeitures of options are based on historical experience.

The
following table represents stock option activity for the three months ended
March 31, 2008:

|                                            |  |                   |         |                 |   |                          |  |  |         | 
|------------------------------------------- |  | ----------------- | ------- | --------------- | - | ------------------------ |  |  | ------- | 
|                                            |  | Number of
 Shares |         | Exercise
 Price |   | Remaining
 Contract Life | 
|                                            |  |                   |         |                 |   |                          | 
|Outstanding
 options at beginning of period |  |                   | 90,000  |                 | $ | 18.93                    |  |  | 2.60Yrs | 
|Granted                                     |  |                   | 22,000  |                 | $ | 11.39                    |  |  |         | 
|Canceled                                    |  |                   | (1,500  | )               | $ | 18.18                    |  |  |         | 
|                                            |  |                   |         |                 |   |                          |  |  |         | 
|Outstanding
 options at end of period       |  |                   | 110,500 |                 | $ | 17.44                    |  |  | 2.88Yrs | 
|                                            |  |                   |         |                 |   |                          |  |  |         | 
|Outstanding
 exercisable at end of period   |  |                   | 58,300  |                 | $ | 20.04                    |  |  | 1.87Yrs | 
|                                            |  |                   |         |                 |   |                          |  |  |         | 

(2)
AVAILABLE-FOR-SALE SECURITIES

Upon
adoption of SFAS No. 115 - Accounting for
Certain Investments in Debt and EquitySecurities, management has
determined that the companys portfolio is best characterized as
Available-For-Sale. SFAS No. 115 requires these securities to be recorded at
their fair market values, with the offsetting unrealized holding gains or
losses being recorded as Comprehensive Income (Loss) in the Equity section of
the Balance Sheet. The adoption of this pronouncement has resulted in an
increase in the carrying value of the companys available-for-sale securities,
as of March 31, 2008 and December 31, 2007, of approximately 94.78% and
149.84%, respectively, over its historical cost.

In
accordance with the provisions of SFAS No. 115, the adjustment in stockholders
equity has been made net of the tax effect had these gains been realized.

The
Company uses the historical cost method in the determination of its realized
and unrealized gains and losses. The following tables summarize the Companys
investments as of:

|                 |  |                |            |           |   |                            |  |                             |            |  |   |            |  
|---------------- |  | -------------- | ---------- | --------- | - | -------------------------- |  | --------------------------- | ---------- |  | - | ---------- | -
|                 |  | March 31, 2008 |           
|                 |  |                |           
|Type of security |  | Cost           |            | FairValue |   | Unrealized
 Holding
 gains |  | Unrealized
 holding
 losses |           
|                 |  |                |            |           |   |                            |  |                             |           
|Equity           |  | $              | 35,667,110 |           | $ | 69,569,236                 |  | $                           | 40,409,648 |  | $ | (6,507,522 | )
|Debt             |  |                | 65,770     |           |   | 30,800                     |  |                             |           |  |   | (34,970    | )
|                 |  |                |            |           |   |                            |  |                             |           
|Total            |  | $              | 35,732,880 |           | $ | 69,600,036                 |  | $                           | 40,409,648 |  | $ | (6,542,492 | )
|                 |  |                |            |           |   |                            |  |                             |           

F-10

---



DAXOR
CORPORATION AND SUBSIDIARY
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2008 and 2007 (Continued)
(Unaudited)

|                 |  |                   |            |             |   |                           |  |                             |            |  |   |            |  
|---------------- |  | ----------------- | ---------- | ----------- | - | ------------------------- |  | --------------------------- | ---------- |  | - | ---------- | -
|                 |  | December 31, 2007 |           
|                 |  |                   |           
|Type of security |  | Cost              |            | Fair
 Value |   | Unrealized
 holding gains |  | Unrealized
 holding
 losses |           
|                 |  |                   |            |             |   |                           |  |                             |           
|Equity           |  | $                 | 29,802,511 |             | $ | 74,572,643                |  | $                           | 47,224,495 |  | $ | (2,454,363 | )
|Debt             |  |                   | 184,646    |             |   | 346,550                   |  |                             | 161,904    |  |   |           |  
|                 |  |                   |            |             |   |                           |  |                             |            |  |   |            |  
|Total            |  | $                 | 29,987,157 |             | $ | 74,919,193                |  | $                           | 47,386,399 |  | $ | (2,454,363 | )
|                 |  |                   |            |             |   |                           |  |                             |            |  |   |            |  

At
March 31, 2008 the securities held by the Company had a market value of
$69,600,036 and a cost basis of $35,732,880 resulting in a net unrealized gain
of $33,867,156 or 94.78% of cost.

At
December 31, 2007, the securities held by the Company had a market value of
$74,919,193 and a cost basis of $29,987,157 resulting in a net unrealized gain
of $44,932,036 or 149.84% of cost.

At
March 31, 2008 and December 31, 2007, marketable securities primarily consist
of preferred and common stocks of utility companies, and are valued at fair
value. Debt securities consist of corporate bonds and notes at March 31, 2008
and these items have a cost of $65,770 and are scheduled to mature at various
dates through May 2048.

(3) Valuation
and Qualifying allowance

The allowance
for doubtful accounts for the quarters ended March 31, 2008 and 2007 were as
follows:

|                                |  |                              |        |                               |   |                          |  |                           |   |  |   |        | 
|------------------------------- |  | ---------------------------- | ------ | ----------------------------- | - | ------------------------ |  | ------------------------- | - |  | - | ------ | 
|                                |  |                              |        |                               |   |                          |  |                           |   |  |   |        | 
|Classifications                 |  | Balance at
Beginning of Year |        | Charged to
Costs and Expenses |   | Deductions
From Reserves |  | Balance at
End of
Quarter |  
|                                |  |                              |        |                               |   |                          |  |                           |  
|Quarter ended March 31, 2007    |  |                              |        |                               |   |                          |  |                           |   |  |   |        | 
|Allowance for Doubtful Accounts |  |                              | 34,163 |                               |   |                         |  |                           |  |  |   | 34,163 | 
|Quarter ended March 31, 2008    |  |                              |        |                               |   |                          |  |                           |   |  |   |        | 
|Allowance for Doubtful Accounts |  | $                            | 57,655 |                               | $ |                         |  | $                         |  |  | $ | 57,655 | 

There was no
inventory reserve recorded for the quarters ended March 31, 2008 and 2007. The
inventory reflects proper valuation for slow moving and obsolete items.

(4) SEGMENT
ANALYSIS

The Company
has two operating segments: the sale of blood volume analysis equipment and
related services, and cryobanking services which encompasses blood and semen
storage and related services. In addition, the Company reports an additional
segment, Investment Activity, although it is not deemed to be an operating
segment.

The
following table summarizes the results of each segment described above for the
three months ended March 31, 2008.

F-11

---



DAXOR CORPORATION AND SUBSIDIARY 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 
March 31, 2008 and 2007 (Continued) 
(Unaudited)

|                                                           |  |                                       |            |                              |   |                    |   |       |            |   |   |            |  
|---------------------------------------------------------- |  | ------------------------------------- | ---------- | ---------------------------- | - | ------------------ | - | ----- | ---------- | - | - | ---------- | -
|                                                           |  | March 31, 2008                        |           
|                                                           |  |                                       |           
|                                                           |  | Equipment
 Sales &
 Related
 Services |            | Cryobanking& RelatedServices |   | InvestmentActivity |   | Total |           
|                                                           |  |                                       |            |                              |   |                    |   |       |           
|                                                           |  |                                       |            |                              |   |                    |   |       |            |   |   |            |  
|Revenues                                                   |  | $                                     | 323,780    |                              | $ | 97,133             |   | $     |           |   | $ | 420,913    |  
|Cost of sales                                              |  |                                       | 138,614    |                              |   | 13,400             |   |       |           |   |   | 152,014    |  
|Research and development expenses                          |  |                                       | 559,309    |                              |   | 48,242             |   |       |           |   |   | 607,551    |  
|Selling, general and administrative
 expenses              |  |                                       | 770,595    |                              |   | 159,554            |   |       |           |   |   | 930,149    |  
|                                                           |  |                                       |            |                              |   |                    |   |       |            |   |   |            |  
|Operating loss                                             |  |                                       | (1,144,738 | )                            |   | (124,063           | ) |       |           |   |   | (1,268,801 | )
|                                                           |  |                                       |            |                              |   |                    |   |       |            |   |   |            |  
|Investment income, net                                     |  |                                       |            |                              |   |                    |   |       |            |   |   |            |  
|Dividends                                                  |  |                                       |           |                              |   |                   |   |       | 630,782    |   |   | 630,782    |  
|Gain on sales of securities, net                           |  |                                       |           |                              |   |                   |   |       | 5,830,999  |   |   | 5,830,999  |  
|Mark to market of short positions                          |  |                                       |           |                              |   |                   |   |       | 2,176,041  |   |   | 2,176,041  |  
|Administrative expenses relating to
 portfolio investments |  |                                       |           |                              |   |                   |   |       | (21,414    | ) |   | (21,414    | )
|                                                           |  |                                       |            |                              |   |                    |   |       |            |   |   |            |  
|Total Investment income, net                               |  |                                       |           |                              |   |                   |   |       | 8,616,408  |   |   | 8,616,408  |  
|                                                           |  |                                       |            |                              |   |                    |   |       |            |   |   |            |  
|                                                           |  |                                       |            |                              |   |                    |   |       |            |   |   |            |  
|Interest expense, net                                      |  |                                       | (8,684     | )                            |   |                   |   |       | (20,831    | ) |   | (29,515    | )
|Other income                                               |  |                                       | 2,870      |                              |   | 46                 |   |       |           |   |   | 2,916      |  
|                                                           |  |                                       |            |                              |   |                    |   |       |            |   |   |            |  
|                                                           |  |                                       |            |                              |   |                    |   |       |            |   |   |            |  
|Income (loss) before income taxes                          |  |                                       | (1,150,552 | )                            |   | (124,017           | ) |       | 8,595,577  |   |   | 7,321,008  |  
|Income tax expense                                         |  |                                       |           |                              |   |                   |   |       |           |   |   |           |  
|                                                           |  |                                       |            |                              |   |                    |   |       |            |   |   |            |  
|                                                           |  |                                       |            |                              |   |                    |   |       |            |   |   |            |  
|Net income (loss)                                          |  | $                                     | (1,150,552 | )                            | $ | (124,017           | ) | $     | 8,595,577  |   | $ | 7,321,008  |  
|                                                           |  |                                       |            |                              |   |                    |   |       |            |   |   |            |  
|                                                           |  |                                       |            |                              |   |                    |   |       |            |   |   |            |  
|Total assets                                               |  | $                                     | 3,817,377  |                              | $ | 210,475            |   | $     | 77,442,739 |   | $ | 81,470,591 |  
|                                                           |  |                                       |            |                              |   |                    |   |       |            |   |   |            |  



F-12

---



DAXOR CORPORATION AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2008 and 2007 (Continued)
(Unaudited)

The following
table summarizes the results of each segment described above for the three
months ended March 31, 2007

|                                                            |  |                                          |            |                                    |   |                       |   |       |            |   |   |            |  
|----------------------------------------------------------- |  | ---------------------------------------- | ---------- | ---------------------------------- | - | --------------------- | - | ----- | ---------- | - | - | ---------- | -
|                                                            |  | March 31, 2007                           |           
|                                                            |  |                                          |           
|                                                            |  | Equipment
  Sales &
  Related
  Services |            | Cryobanking
  & Related
  Services |   | Investment
  Activity |   | Total |           
|                                                            |  |                                          |            |                                    |   |                       |   |       |           
|                                                            |  |                                          |            |                                    |   |                       |   |       |            |   |   |            |  
|Revenues                                                    |  | $                                        | 394,226    |                                    | $ | 111,656               |   | $     |           |   | $ | 505,882    |  
|Cost of
  sales                                             |  |                                          | 139,060    |                                    |   | 12,475                |   |       |           |   |   | 151,535    |  
|Research and
  development expenses                         |  |                                          | 548,190    |                                    |   | 56,041                |   |       |           |   |   | 604,231    |  
|Selling,
  general and administrative expenses              |  |                                          | 754,780    |                                    |   | 201,203               |   |       |           |   |   | 955,983    |  
|                                                            |  |                                          |            |                                    |   |                       |   |       |            |   |   |            |  
|Operating
  loss                                            |  |                                          | (1,047,804 | )                                  |   | (158,063              | ) |       |           |   |   | (1,205,867 | )
|                                                            |  |                                          |            |                                    |   |                       |   |       |            |   |   |            |  
|                                                            |  |                                          |            |                                    |   |                       |   |       |            |   |   |            |  
|Investment
  income                                         |  |                                          |            |                                    |   |                       |   |       |            |   |   |            |  
|Dividends                                                   |  |                                          |           |                                    |   |                      |   |       | 711,429    |   |   | 711,429    |  
|Gain on sales of securities, net                            |  |                                          |           |                                    |   |                      |   |       | 1,626,430  |   |   | 1,626,430  |  
|Mark to market of short positions                           |  |                                          |           |                                    |   |                      |   |       | 2,014,798  |   |   | 2,014,798  |  
|Administrative expenses relating to
  portfolio investments |  |                                          |           |                                    |   |                      |   |       | (12,138    | ) |   | (12,138    | )
|                                                            |  |                                          |            |                                    |   |                       |   |       |            |   |   |            |  
|Total Investment income, net                                |  |                                          |           |                                    |   |                      |   |       | 4,340,519  |   |   | 4,340,519  |  
|                                                            |  |                                          |            |                                    |   |                       |   |       |            |   |   |            |  
|                                                            |  |                                          |            |                                    |   |                       |   |       |            |   |   |            |  
|Interest
  expense, net                                     |  |                                          | (5,935     | )                                  |   |                      |   |       | (71,478    | ) |   | (77,413    | )
|Other income                                                |  |                                          | 2,755      |                                    |   |                      |   |       |           |   |   | 2,755      |  
|                                                            |  |                                          |            |                                    |   |                       |   |       |            |   |   |            |  
|                                                            |  |                                          |            |                                    |   |                       |   |       |            |   |   |            |  
|Income
  (loss) before income taxes                         |  |                                          | (1,050,984 | )                                  |   | (158,063              | ) |       | 4,269,041  |   |   | 3,059,994  |  
|Income tax
  expense                                        |  |                                          |           |                                    |   |                      |   |       |           |   |   |           |  
|                                                            |  |                                          |            |                                    |   |                       |   |       |            |   |   |            |  
|                                                            |  |                                          |            |                                    |   |                       |   |       |            |   |   |            |  
|Net income
  (loss)                                         |  | $                                        | (1,050,984 | )                                  | $ | (158,063              | ) | $     | 4,269,041  |   | $ | 3,059,994  |  
|                                                            |  |                                          |            |                                    |   |                       |   |       |            |   |   |            |  
|                                                            |  |                                          |            |                                    |   |                       |   |       |            |   |   |            |  
|Total assets                                                |  | $                                        | 2,220,626  |                                    | $ | 124,739               |   | $     | 81,122,906 |   | $ | 83,468,271 |  
|                                                            |  |                                          |            |                                    |   |                       |   |       |            |   |   |            |  

(5)  PROPERTY AND EQUIPMENT

Property
and equipment as at March 31, 2008 and December 31, 2007, consists of:

|                                            |  |                  |            |                     |   |            |  
|------------------------------------------- |  | ---------------- | ---------- | ------------------- | - | ---------- | -
|                                            |  | March 31,
  2008 |            | December 31,
  2007 |  
|                                            |  |                  |            |                     |  
|                                            |  |                  |            |                     |   |            |  
|Machinery
  and equipment                   |  | $                | 1,286,856  |                     | $ | 1,161,413  |  
|BVA
  Equipment on trial                    |  |                  | 782,000    |                     |   | 782,000    |  
|Land and
  Land Improvements                |  |                  | 196,991    |                     |   | 196,991    |  
|Buildings                                   |  |                  | 598,422    |                     |   | 598,422    |  
|Furniture
  and fixtures                    |  |                  | 356,862    |                     |   | 352,972    |  
|Leasehold
  improvements                    |  |                  | 594,535    |                     |   | 591,866    |  
|                                            |  |                  |            |                     |   |            |  
|Total Cost                                  |  | $                | 3,815,666  |                     | $ | 3,683,664  |  
|Accumulated
  depreciation and amortization |  |                  | (1,693,829 | )                   |   | (1,625,170 | )
|                                            |  |                  |            |                     |   |            |  
|Property and
  equipment, net               |  | $                | 2,121,837  |                     | $ | 2,058,494  |  
|                                            |  |                  |            |                     |   |            |  

Depreciation
expense for the three months ended March 31, 2008 and March 31, 2007 was
respectively $ 68,659 and $52,531.

On January 3,
2007, Daxor closed on the purchase of 3.5 acres of land at 107 and 109 Meco
Lane, Oak Ridge, Tennessee that contains two separate 10,000 square foot
buildings.  The buildings were
constructed in 2004 and each structure is a single story steel frame with metal
shell and roof constructed on a concrete slab.
The total purchase price for the land and buildings including closing
costs was $784,064.

F-13

---



DAXOR CORPORATION AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2008 and 2007 (Continued)
(Unaudited)

The build out
of the buildings in Oak Ridge commenced in the beginning of July of 2007 after
the Company received the necessary state and local permits and licenses and the
company moved in to the new buildings during the first week of October 2007.

(6)  LOANS AND MORTGAGE PAYABLE

LOANS
PAYABLE

At
March 31, 2008 and December 31, 2007, the Company has a bank note payable of
$1,400,000 and $1,500,000 respectively which is classified as a current
liability. The note is renewable on May 28, 2008 for a period of one year. The
note bears interest at approximately 3.75% and is secured by certain marketable
securities of the Company.

The
interest expense on this note for the three months ended March 31, 2008 and
2007 was $18,027 and $24,998, respectively.

Short-term
debt to brokers (margin debt), is secured by the Companys marketable
securities, and totaled $1,192,418 at March 31, 2008 and $ 1,814,303 at
December 31, 2007.

MORTGAGE
PAYABLE

Daxor
financed the purchase of the land and buildings in Oak Ridge, Tennessee with a
$500,000 10-year mortgage, with the first five years fixed at 7.49%. On January
2, 2012 there is a single payment of $301,972 for the remaining principal and
interest on the mortgage. The Company has the option of making this payment or
refinancing the mortgage for an additional five year term at a fixed rate of
interest that would be set on January 2, 2012.

The future payments of principal on the mortgage by twelve month period end are
as follows:

|         |          |          |           
|-------- | -------- | -------- | ----------
|03/31/09 | 03/31/10 | 03/31/11 | Thereafter
|         |          |          |           
|         |          |          |           
|$38,102  | $41,055  | $44,237  | $335,404  

At March 31,
2008, the remaining principal due on the mortgage for the land and buildings in
Oak Ridge, Tennessee is $ 458,798.  Of
this amount, $38,102 is due before March 31, 2009 and the remaining $420,696 is
due after that date.

(7)  PUT AND CALL OPTIONS AT FAIR VALUE

As
part of the companys investment strategy, put and call options are sold on
various stocks the company is willing to buy or sell. The premiums received are
deferred until such time as they are exercised or expire. In accordance with
SFAS No. 133 - Accounting for Derivative
Instruments and Hedging Activities,these options are marked to
market for each reporting period using readily available market quotes, and
this fair value adjustment is recorded as a gain or loss in the Statement of
Operations.

Upon
exercise, the value of the premium will adjust the basis of the underlying
security bought or sold. Options that expire are recorded as income in the
period they expire.

The following summarizes the Companys Put and Call Options
as of March 31, 2008 and December 31, 2007:

|                     |  |               |           |                     |  |                |  |  |           |  | 
|-------------------- |  | ------------- | --------- | ------------------- |  | -------------- |  |  | --------- |  | 
|Put and Call Options |  | Selling price |           | Fair Market
  value |  | UnrealizedGain | 
|                     |  |               |           |                     |  |                |  | 
|March 31,
  2008     |  |               | 9,813,213 |                     |  | 7,685,008      |  |  | 2,128,205 | 
|December 31,
  2007  |  |               | 7,645,833 |                     |  | 5,972,632      |  |  | 1,673,201 | 

(8)   SECURITIES BORROWED AT FAIR VALUE

At
March 31, 2008 and December 31, 2007, the Company maintained short positions in
certain marketable securities. The liability for short sales of securities is
included in Securities borrowed at fair market value in the accompanying
balance sheets. The cost basis of these positions or proceeds for these short
sales were $4,370,084 and $18,712,876 at March 31, 2008 and December 31, 2007
respectively and had respective market values of $4,245,368 and $20,362,259,
resulting in mark to market adjustments of $124,716 and ($1,649,383) at March
31, 2008 and December 31, 2007.

F-14

---



DAXOR CORPORATION AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2008 and 2007 (Continued)
(Unaudited)

(9) STOCK
OPTIONS

In June 2004,
the Company created the 2004 Stock Option Plan in an effort to provide
incentive to employees, officers, agents, consultants, and independent
contractors through proprietary interest. The Board of Directors shall act as
the Plan Administrator, and may issue these options at its discretion. The
maximum number of shares that may be issued under this Plan is 200,000 or 5% of
the Companys outstanding shares, whichever is greater. Prior to June 2004, the
Company issued options to various employees under the previous Stock Option
Plan that was also administered by the Board of Directors. All issuances have
varying vesting and expiration timelines. As at March 31, 2008 and 2007, 58,300
and 78,400 of the outstanding options were exercisable, respectively.

(10)  CURRENT INCOME TAXES

Under
Internal revenue code section 542, a company is defined as a personal holding company
(PHC) if it meets both an ownership and income test. The ownership test is met if a
company has five or fewer shareholders who own more than 50% of the company. Daxor meets
the ownership test..  The income test is met if PHC income items such as dividends,
interest and rents exceed 60% of adjusted ordinary gross income. Adjusted
ordinary gross income is defined as all items of income except capital gains.  For
the three months ended March 31, 2008, more than 60% of Daxors adjusted gross income
came from items defined as PHC income. Accordingly the Company is a PHC, as it meets both
the ownership and income tests.

As
a result, the Company is subject to a PHC income tax on any of its undistributable PHC
income. For the three months ending March 31, 2008, Daxors undistributable PHC
income was determined to be approximately $7,300,000. Under FASB No. 109, the Company
accrues income taxes in interim periods based upon its estimated annual effective interest
rate. Assuming there is no change in PHC income for the remainder of 2008, then the
effective rate would be equal to the statutory rate for the quarter ended March 31, 2008
and the calculated PHC tax provision at March 31, 2008 would be approximately $1,100,000.

Determining
the PHC tax liability requires computing the Companys undistributed PHC
income for the year and taxing such PHC income at the statutory rate of 15% (or
during interim periods using the estimated annual effective PHC income tax rate).
Undistributed PHC income is the Companys current year taxable income, exclusive of
the net operating loss carry forward deduction which is permitted for regular tax purposes
and adjusted for certain allowable deductions.

The
most significant of these deductions is long-term capital gains, which are approximately
$43,000 for the three months ending March 31, 2008.  During the three months ending
March 31, 2008, the Company had short-term capital gains totaling approximately
$5,800,000. Short term capital gains are not a deduction for PHC tax purposes, which has
given rise to the Companys estimated undistributed PHC income.

Management
plans to eliminate its undistributed PHC income before the end of the year. This will be
accomplished by either eliminating its undistributable PHC income by paying this income
out as a dividend before the end of the year, or by realizing losses on the sale of
certain securities or by a combination of both of these activities. Accordingly,
management has determined that no current provision for income taxes or related liability
attributable to the PHC income tax is necessary as of and for the three months ended March
31, 2008.

(11)  DEFERRED INCOME TAXES

Deferred
income taxes result from differences in the recognition of gains and losses on
marketable securities, as well as operating loss carry forwards, for tax and
financial statement purposes. The deferred income tax results in a liability
for the marketable securities, while the operating loss carry forwards result
in a deferred tax asset.

The
deferred tax liability that results from the marketable securities does not
flow through the Statement of Operations due to the classification of the
marketable securities as available-for-sale. Instead, any increase or decrease
in the deferred tax liability is recorded as an adjustment to Accumulated Other
Comprehensive Income which is in the Stockholders Equity section of the
Balance Sheet.

At
March 31, 2008 the Company has approximately $9.7 million in net operating loss
available as a carry forward. These losses will expire between the years ending
December 31, 2015 and 2026 and give rise to deferred tax assets. However, a
valuation allowance has been recorded for the entire deferred tax asset as a
result of uncertainties regarding the realization of the asset due to the
history of losses and the variability of operating results.

While
the Company has a deferred tax liability on unrealized portfolio gains, at
present it is not managements intention to liquidate its holdings in order to
utilize these loss carryovers. Some holdings may be periodically liquidated on
an involuntary basis when the Company receives a cash only offer as the result
of a merger. If there is an option to receive stock instead of cash, the
Company will usually elect to receive stock.

F-15

---



DAXOR CORPORATION AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2008 and 2007 (Continued)
(Unaudited)

The
deferred tax computations at March 31, 2008 and December 31, 2007, computed at
federal statutory rates of 35%, are as follows:

|                                    |  |      |            |      |   |            |  
|----------------------------------- |  | ---- | ---------- | ---- | - | ---------- | -
|                                    |  | 2008 |            | 2007 |  
|                                    |  |      |            |      |  
|Deferred tax
  assets:              |  |      |            |      |   |            |  
|Net
  operating loss carry forwards |  | $    | 3,399,311  |      | $ | 3,410,396  |  
|Valuation
  allowance               |  |      | (3,399,311 | )    |   | (3,410,396 | )
|                                    |  |      |            |      |   |            |  
|Total
  deferred tax assets         |  | $    | 0          |      | $ | 0          |  
|                                    |  |      |            |      |   |            |  
|                                    |  |      |            |      |   |            |  
|Deferred tax
  liabilities          |  | $    | 11,853,505 |      | $ | 15,726,213 |  
|                                    |  |      |            |      |   |            |  

(12)  CERTAIN CONCENTRATIONS AND CONTINGENCIES

Financial
instruments which potentially subject the Company to concentrations of credit
risk consist primarily of the common stock of marketable electric utilities. At
March 31, 2008, stocks representing 98.76% of the market value of common stocks
held by the Company were listed on either the New York Stock Exchange (NYSE) or
the American Stock Exchange (AMEX).  The
Company maintains its investments in six different brokerage accounts, four at
UBS, one at Merrill Lynch and one at JP Morgan Chase. The limits of the
insurance offered by the Securities Investor Protection Corporation
(SIPC) is up to $100,000 for the total amount of cash on deposit and up to
$500,000 for the total amount of securities held at Merrill Lynch and JP Morgan
Chase. UBS provides supplemental insurance up to the face value of the
securities in excess of the SIPC limit of $500,000.

Each of these
brokerage houses is well known in the industry and management does not believe
that these securities bear any risk of loss over and above the basic risk that
a security bears through the normal activity of the securities markets.
However, as at March 31, 2008 the fair market value of securities in excess of
the SIPC insured limit is $24,773,978 and the cash on deposit in excess of the
insured limit is $4,721,463.

For the three
months ended March 31, 2008 there were three customers (hospitals) that
accounted for 38.02% of the Companys total consolidated sales.   Management believes that the loss of any
one customer would have an adverse effect on the Companys consolidated
business for a short period of time. All three of these hospitals have purchased
their BVA-100 equipment. The Company has not had any situations in which a
hospital, after having purchased a blood volume analyzer, discontinued
purchasing Volumex kits. This suggests that, when more hospitals purchase
equipment, they will continue with ongoing purchase of Volumex kits.  The Company continues to seek new customers,
so that any one hospital will represent a smaller percentage of overall sales.

The Companys
Volumex syringes are filled by an FDA approved radio pharmaceutical manufacturer.
This manufacturer is the only one approved by the FDA in the United States to
manufacture Volumex for interstate commerce. If this manufacturer were to cease
filling the Volumex syringes for Daxor before the Company had a chance to make
alternative arrangements, the effect on Daxors business could be material.

Since December
31, 2007, Daxor has not received any verbal or written communication from the
staff of the Northeast Regional Office of the United States Securities and
Exchange Commission regarding any unresolved issues.  These unresolved issues were discussed in detail in the
Forms  10-K for the years ended December
31, 2007 and 2006 as well as the 10-Qs for 2007.

(13)  Related Party Transactions

The
Company subleases a portion of its New York City office space to the President
of the Company for five hours per week. This sublease agreement has no formal
terms and is executed on a month to month basis. The amount of rental income
received from the President of the Company in the quarters ended March 31, 2008
and 2007 was $2,870 and $2,755.

Jonathan
Feldschuh is the co-inventor of the BVA-100 Blood Volume Analyzer and is the
son of Dr. Joseph Feldschuh.  He is
expected to provide a limited amount of consultative help in the filing of the
additional patents in 2008.

(14)  Research and Development Costs

All
research and development costs, as defined in SFAS No. 2  Accounting for Research and Development Costs,
are expensed in the period they are incurred.

F-16

---



DAXOR CORPORATION AND SUBSIDIARY 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 
March 31, 2008 and 2007 (Continued) 
(Unaudited)

Research
and development costs for the three months ended March 31, 2008 and 2007 were
$607,551 and $604,231, respectively.

(15)
Subsequent Events

There
were no subsequent events which took place after March 31, 2008 which required
disclosure in this Form 10-Q.

(16) Recently
Issued Accounting Pronouncements

In June 2006,
The FASB issued Interpretation No. 48 Accounting for Uncertainty in Income
Taxesan interpretation of FASB Statement No. 109 (FIN 48). This
Interpretation clarifies the accounting for uncertainty in income taxes
recognized in an enterprises financial statements in accordance with FASB
Statement No. 109, Accounting for Income Taxes. FIN 48 prescribes a
recognition threshold and measurement attribute for the financial statement
recognition and measurement of a tax position taken or expected to be taken in
a tax return. This Interpretation also provides guidance on derecognition,
classification, interest and penalties, accounting in interim periods,
disclosure, and transition. This Interpretation is effective for fiscal years
beginning after December 15, 2006. Earlier application of the provisions of
this Interpretation is encouraged if the enterprise has not yet issued
financial statements, including interim financial statements, in the period
this Interpretation is adopted. Management does not expect that the application
of this standard will have any effect on the Companys results of operations or
its financial condition.

In September
2006, the FASB issued SFAS No. 157, Fair Value Measurements (SFAS 157), to
define fair value, establish a framework for measuring fair value in accordance
with generally accepted accounting principles (GAAP) and expand disclosures
about fair value measurements. SFAS 157 requires quantitative disclosures using
a tabular format in all periods (interim and annual) and qualitative
disclosures about the valuation techniques used to measure fair value in all
annual periods. SFAS 157 will be effective for the Company beginning January 1,
2008. The Company is currently evaluating the impact of adopting SFAS 157.

In September
2006, the SEC staff issued Staff Accounting Bulletin (SAB) Topic 1M (SAB 108),
Financial Statements - Considering the Effects of Prior Year Misstatements
when Quantifying Misstatements in Current Year Financial Statements, which is
effective for the 2007 year. SAB 108 provides guidance on how prior year
misstatements should be taken into consideration when quantifying misstatements
in current year financial statements for the purpose of determining whether the
financial statements are materially misstated. Under this guidance, companies
should take into account both the effect of a misstatement on the current year
balance sheet as well as the impact upon the current year income statement in
assessing the materiality of a current year misstatement. Once a current year
misstatement has been quantified, the guidance in SAB Topic 1M, Financial
Statements - Materiality, (SAB 99) should be applied to determine whether the
misstatement is material. The implementation of SAB 108 did not have any impact
on the Companys financial statements.

In February
2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets
and Financial Liabilities (SFAS 159). SFAS 159 expands opportunities to use
fair value measurements in financial reporting and permits entities to choose
to measure many financial instruments and certain other items at fair value.
SFAS 159 will be effective for the Company on January 1, 2008. The Company is
currently evaluating the impact of adopting SFAS 159 on its financial
statements.

In June 2007,
the Emerging Issues Task Force (EITF) issued EITF 07-3, Accounting for
Nonrefundable Advance Payments for Goods or Services to Be Used in Future
Research and Development Activities, which provides guidance on the accounting
for certain nonrefundable advance payments for goods or services that will be
used or rendered for future research and development activities. This issue is
effective prospectively for fiscal years beginning after December 15, 2007, or
fiscal 2009 for the Company. We are still assessing the potential impact of
adoption.

F-17

---



DAXOR CORPORATION AND SUBSIDIARY 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 
March 31, 2008 and 2007 (Continued) (Unaudited)

In December
2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated
Financial Statements  an amendment of ARB No. 51 (SFAS 160). SFAS 160
requires that ownership interests in subsidiaries held by parties other than
the parent, and the amount of consolidated net income, be clearly identified,
labeled, and presented in the consolidated financial statements within equity,
but separate from the parents equity. It also requires once a subsidiary is
deconsolidated, any retained noncontrolling equity investment in the former
subsidiary be initially measured at fair value. Sufficient disclosures are
required to clearly identify and distinguish between the interests of the
parent and the interests of the noncontrolling owners. SFAS 160 will be
effective for the Company beginning January 1, 2009. The Company is currently
evaluating the impact of the provisions of SFAS 160 on its financial position,
results of operations and cash flows and does not believe the impact of the
adoption will be material.

In December
2007, the Securities and Exchange Commission (SEC) issued Staff Accounting Bulletin No. 110 (SAB110). SAB 110 amends and replaces
Question 6 of Section D.2 of Topic 14, Share-Based
Paymentof the Staff Accounting Bulletin series. Question 6 of
Section D.2 of Topic 14 expresses the views of the staff regarding the use of
the simplified method in developing an estimate of expected term of plain
vanilla share options and allows usage of the simplified method for share
option grants prior to December 31, 2007. SAB 110 allows public companies which
do not have historically sufficient experience to provide a reasonable estimate
to continue use of the simplified method for estimating the expected term of
plain vanilla share option grants after December 31, 2007. We currently use
the simplified method to estimate the expected term for share option grants
as we do not have enough historical experience to provide a reasonable
estimate. We will continue to use the simplified method until we have enough
historical experience to provide a reasonable estimate of expected term in
accordance with SAB 110. SAB 110 is effective for the Company on January 1,
2008.

In December
2007, the FASB issued SFAS No. 141(R), Business Combinations (revised 2007).
SFAS No. 141(R) applies the acquisition method of accounting for business
combinations established in SFAS No. 141 to all acquisitions where the acquirer
gains a controlling interest, regardless of whether consideration was
exchanged. Consistent with SFAS No. 141, SFAS No. 141(R) requires the acquirer
to fair value the assets and liabilities of the acquiree and record goodwill on
bargain purchases, with main difference the application to all acquisitions
where control is achieved. SFAS No. 141(R) is effective for financial
statements issued for fiscal years beginning after December 15, 2008 and will
be adopted by the Company in the first quarter of fiscal year 2009. The Company
does not expect that the adoption of SFAS No. 141(R) will have a material
impact on our financial condition or results of operation.

In March 2008,
the FASB issued SFAS No. 161, Disclosures about Derivative Instruments and
Hedging Activitiesan amendment of FASB Statement No. 133. The use and
complexity of derivative instruments and hedging activities have increased
significantly over the past several years. Constituents have expressed concerns
that the existing disclosure requirements in FASB Statement No. 133, Accounting for Derivative Instruments and Hedging
Activities, do not provide adequate information about how derivative
and hedging activities affect an entitys financial position, financial
performance, and cash flows. Accordingly, this Statement requires enhanced
disclosures about an entitys derivative and hedging activities and thereby
improves the transparency of financial reporting. This Statement is effective
for financial statements issued for fiscal years and interim periods beginning
after November 15, 2008, with early application encouraged. This Statement
encourages, but does not require, comparative disclosures for earlier periods
at initial adoption. The Company is currently evaluating the impact of the
provisions of SFAS No. 161 on its financial position, results of operations and
cash flows and does not believe the impact of the adoption will be material.

F-18

---



ITEM 2. MANAGEMENTS DISCUSSION
AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF 
OPERATIONS

RECENT
DEVELOPMENTS

The
Centers for Medicare and Medicaid Services (CMS) implemented a significant
policy change affecting the reimbursement for all diagnostic radiopharmaceutical
products and contrast agents which became effective as of January 1, 2008.
Diagnostic radiopharmaceuticals such as Daxors Volumex will not be separately
reimbursable by Medicare for outpatient services. At this time, it is unclear
if this policy change will also be implemented by private third party health
insurance companies or non-hospital providers.

The
previous reimbursement for hospital outpatients includes payment for both the
cost of the procedure to perform a blood volume analysis (BVA) and the
radiopharmaceutical (Daxors Volumex radiopharmaceutical). CMSs new policy
became effective as of January 1, 2008 and will only include the reimbursement
for the procedure and would require the hospital to absorb the cost of the
radiopharmaceutical. There will be an upward adjustment for the procedure code
to include some of the costs of the radiopharmaceutical. However, this upward
adjustment may not entirely cover the costs associated with the procedure and
the radiopharmaceutical.

Many
medical societies and major manufacturers of radiopharmaceuticals and contrast
agents are currently engaged in an aggressive attempt to reverse this ruling.
The Company has had similar issues in the past that have negatively impaired
revenue from operations. This particular issue may have a similar impact.
However, at the present time, the Company is unable to quantify what the effect
of this ruling will be on revenue from operations for the year ending December
31, 2008.

RESULTS OF
OPERATIONS

Three months
ended March 31, 2008 as compared with three months ended March 31, 2007:

Operating Revenues and Expenses

For
the three months ended March 31, 2008, consolidated operating revenues
decreased to $420,913 from $505,882 for the same period in 2007, a decrease of
$84,969 or 16.80%. This decrease was mainly the result of no Blood Volume
Analyzers being sold during the first quarter of 2008 versus the sale of two
Blood Volume Analyzers during the same period in 2007 for a total of $130,500.

For
the three months ended March 31, 2008, revenue from Blood volume kit sales
increased by 24.44% to $294,377 from $236,561 for the same period in 2007. This
can mainly be attributed to an increase in the number of kits sold from 750 in
2007 to 862 during the current period for an increase of 14.93%. A major reason
for the increase in the number of kits sold is that there were 53 Blood Volume
Analyzers placed at March 31, 2008 versus 36 at March 31, 2007. For the three
months ended March 31, 2008, the Company provided 111 Volumex doses free of
charge to facilities utilizing the BVA-100 for research versus 87 during the
same period in 2007. Effective February 1, 2007, the Company raised prices by
approximately 5% on Blood Volume Kits.

-3-

---



The following
table provides gross margin information on Equipment Sales & Related
Services for the three months ended March 31, 2008 and 2007:

|                                      |  |                                                  |         |                                                                   |   |                                             |   |                                             |         |   |   |         |  
|------------------------------------- |  | ------------------------------------------------ | ------- | ----------------------------------------------------------------- | - | ------------------------------------------- | - | ------------------------------------------- | ------- | - | - | ------- | -
|Equipment Sales
 And Related Serivces |  | Kit Sales
 Three
 Months
 Ended
 March 31,
 2008 |         | Equipment
 Sales and
 Other Three
 Months
 Ended
 March 31,
 2008 |   | Total Three
 Months
 Ended
 March 31,
 2008 |   | Total Three
 Months
 Ended
 March 31,
 2007 |        
|                                      |  |                                                  |         |                                                                   |   |                                             |   |                                             |        
|Revenue                               |  | $                                                | 294,377 |                                                                   | $ | 29,403                                      |   | $                                           | 323,780 |   | $ | 394,226 |  
|Cost of Goods Sold                    |  |                                                  | 120,168 |                                                                   |   | 18,446                                      |   |                                             | 138,614 |   |   | 139,060 |  
|Gross Profit (Loss)                   |  | $                                                | 174,209 |                                                                   | $ | 10,957                                      |   | $                                           | 185,166 |   | $ | 255,166 |  
|Gross Profit (Loss) Percentage        |  |                                                  | 59.18   | %                                                                 |   | 37.26                                       | % |                                             | 57.19   | % |   | 64.72   | %

There
were no Blood Volume Analyzers sold during the three months ended March 31,
2008 versus two during the three months ended March 31, 2007. The revenue of
$29,403 for Equipment Sales and Other consists almost entirely of shipping
charges and service contract revenue.

Total
S G & A (selling, general and administrative) and R&D (Research and
Development) costs for Equipment Sales and Related Services were $1,329,904 for
the three months ended March 31, 2008 versus $ 1,302,970 for the same period in
2007, for an increase of $26,934 or 2.07%. The main reason for this was
increased payroll and related costs of $17,379 for the three months ended March
31, 2008 as compared to the same period in 2007.

Research
& Development expenses for Equipment Sales and Related Services were
$559,309 for the three months ended March 31, 2008 vs. $548,190 for the same
period in 2007 which is an increase of $11,119 or 2.03%. Daxor is committed to
making Blood Volume Analysis a standard of care in at least three different
disease states. In order to achieve this goal, we are continuing to spend time
and money in research and development to get the best product to the market. We
are still working on the following three projects: 1) GFR: Glomerular
Filtration Rate, 2) Total Body Albumin Analysis, and 3) Wipes tests for
radiation contamination/detection. We are also progressing on the next version
of the delivery device for the radioactive dose Volumex. The current version is
the Max-100 which has a patent. The next version, the Max-200 will be
without a needle and should afford the company extended protection with a
second patent when it is completed.

Operating
revenues for the cryobanking segment, which includes both blood banking and
semen banking, decreased to $97,133 in 2008 from $111,656 in 2007, for a
decrease of $14,523 or 13.01%. The main reason for this was a decrease in Semen
Bank Storage fees of $8,602 for the three months ended March 31, 2008 as
compared to 2007.

Total
S G & A (selling, general and administrative) and R&D (Research and
Development) costs for the Cryobanking and related services segment were
$207,796 for the three months ended March 31, 2008 vs. $257,244 for the same
period in 2007, for a decrease of $49,448 or 19.22%. The main reason for this
decrease was a $43,722 reduction in payroll and related expenses for the three
months ended March 31, 2008 as compared to the same period in 2007.

Consolidated Operating Expenses and Cost of Goods Sold

The
consolidated expenses from operations and cost of goods sold for the first
quarter of 2008 were $1,689,714 versus $1,711,749 in 2007 for a decrease of
$22,035 or 1.28%. This decrease in operating expenses and cost of goods sold is
mostly due to a decrease in payroll and related expenses of $26,343 in the
quarter ended March 31, 2008 as compared to the same period in 2007.

-4-

---



INVESTMENT
PORTFOLIO

Dividend Income

Dividend
income earned on the Companys security portfolio for the three months ended
March 31, 2008 was $630,782 versus $711,429 for the same period in 2007 for a
decrease of $80,647 or 11.33%. The main reason for this decrease was the
receipt of a onetime special dividend of $156,200 during the quarter ended
March 31, 2007 on a stock that is no longer included in the Companys available
for sale securities.

Investment Gains

Gains
on the sale of investments were $5,830,999 for the three months ended March 31,
2008 versus $1,626,430 for the same period in 2007 for an increase of
$4,204,569 or 258.52%. For the current quarter, the Company had a gain from the
marking to the market of short positions of stocks and put and call options of
$2,176,041 versus a gain of $2,014,798 for the same period in 2007 for an
increase of $161,243 or 8.00%. Interest expense net of interest income was
$20,831 for the three months ended March 31, 2008 versus $71,478 for the three
months ended March 31, 2007 for a decrease of $50,647 or 70.86%. Administrative
expenses relating to portfolio investments were $21,414 in 2008 versus $ 12,138
for the same period in 2007 for an increase of $9,276 or 76.42%. A detailed
description of investment policies and historical records over the past 15
years was included in the recent 10-K filing for the year ended December 31, 2007.

LIQUIDITY AND
CAPITAL RESOURCES

The
Companys management has pursued a policy of maintaining sufficient liquidity
and capital resources in order to assure continued availability of necessary
funds for the viability and projected growth of all ongoing projects.

At
March 31, 2008 the Company had total assets of $81,470,591 with stockholders
equity of $54,319,391 as compared to total assets of $102,560,500 with
stockholders equity of $54,915,885 at December 31, 2007. At March 31, 2008,
the Company had a net unrealized gain on available for sale securities of
$33,867,156 and a deferred tax liability of $11,853,505 for net unrealized
capital gains on available-for-sale securities of $22,013,651. At December 31,
2007, the company had a net unrealized gain of $44,932,036 and a deferred tax
liability of $15,726,213 for net unrealized capital gains on available-for-sale
securities of $29,205,823. These amounts are included in the calculation of
Total Stockholders Equity. At March 31 2008, the Companys available for sale
securities had a fair market value of $69,600,036 with short-term loans payable
of $2,592,418 and a receivable due from brokers of $5,182,991. The Company has
current liabilities of $26,730,504 which includes the deferred tax liability of
$11,853,505 and the short term loans payable of $2,592,418. The deferred tax
liability would be due if the Company chose to sell its entire portfolio. The
Companys investment portfolio has been a critical source of supplemental
income to partially offset the continuing losses from operations. Without this
income, the Company would have been in a precarious financial situation because
of its operating losses over the past 15 years. The Companys portfolio has
maintained a net value above historical cost for each of the past 93
consecutive quarters.

The
Company currently has adequate resources for the current level of marketing and
research and development expenses for the BVA-100 Blood Volume Analyzer as well
as capital to sustain its localized semen and blood banking services. The
Company may not, at the present time, have adequate resources to expand its
marketing force to all areas of the country. The Company is simultaneously
expanding its research and development efforts to develop additional
instrumentation for renal function testing, specifically glomerular filtration
testing. The Company recently explored the potential for raising additional
capital but the terms would have been disadvantageous to existing shareholders.
The current primary focus is on the BVA-100 Blood Volume Analyzer with respect
to expenditure of resources. The Company anticipates hiring additional regional
managers to the existing sales/marketing team. It is the goal of the marketing
team to develop an individual sales team for each regional manager. The Company
is also expanding its support services personnel.

-5-

---



CRITICAL ACCOUNTING
POLICIES

The
consolidated financial statements and accompanying footnotes included in this
report have been prepared in accordance with accounting principles generally
accepted in the United States with certain amounts based on managements best
estimates and judgments. To determine appropriate carrying values of assets and
liabilities that are not readily available from other sources, management uses
assumptions based on historical results and other factors that they believe are
reasonable. Actual results could differ from those estimates.

The Company
adopted SFAS No. 123R - Share-Based
Payments, effective January 1, 2006, utilizing the modified
prospective method. Under the modified prospective method, compensation cost
is recognized for all share-based payments granted after the effective date and
for all unvested awards granted prior to the effective date. Prior to adoption,
the Company accounted for share-based payments under the recognition and
measurement principles of Accounting Principles Board Opinion No. 25 - Accounting for Stock Issued to Employees,
and related interpretations.

The Company
recognized $17,855 and $4,518, respectively in total stock-based compensation
expense during the three months ended March 31, 2008 and March 31, 2007.

Total unvested
stock-based compensation expense was $51,945 at March 31, 2008 and had a total
weighted average remaining term of 0.71 years. See Footnote #1 for more
information on stock-based compensation.

The following
is a summary of the accounting policies that the Company has deemed critical
for reporting purposes in Form 10-Q at March 31, 2008. However, a comprehensive
discussion of the Companys critical accounting policies and management
estimates is included in Managements Discussion and Analysis of Financial
Condition and Results of Operations in the Companys Annual Report on Form 10-K
for the year ended December 31, 2007. There have been no significant
changes in critical accounting policies or management estimates since the year
ended December 31, 2007.

Available-for-Sale Securities

Available-for-sale
securities represent investments in debt and equity securities (primarily
common and preferred stock of utility companies) that management has determined
meet the definition of available-for-sale securities under SFAS No. 115 - Accounting for Certain Investments in Debt and Equity
Securities. Accordingly, these investments are stated at fair market
value and all unrealized holding gains or losses are recorded in the
Stockholders Equity section as Accumulated Other Comprehensive Income (Loss).
Conversely, all realized gains, losses and earnings are recorded in the
Statement of Operations under Other Income (Expense).

The
company will also periodically engage in short selling of common stock. When
this occurs, the short position is marked to the market and this adjustment is recorded
in the Statement of Operations. Any gain or loss is recorded in the period
presented.

Historical
cost is used by the Company to determine all gains and losses, and fair market
value is obtained by readily available market quotes on all securities.

The Companys
investment goals, strategies and policies are as follows:

| |    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
| | -- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| | 1. | The
 Companys investment goals are capital preservation and maintaining returns
 on capital with a high degree of safety.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
| |    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
| | 2. | The Company
 maintains a diversified securities portfolio comprised primarily of electric
 utility common and preferred stocks. The Company also sells covered calls on
 portions of its portfolio and also sells puts on stocks it is willing to own.
 It also sells uncovered calls and may have short positions in common stock up
 to 15% of the value of the portfolio. The Companys short position may
 temporarily rise to 15% of the Companys portfolio without any specific
 action because of changes in valuation, but should not exceed this amount.
 The Companys investment policy is to maintain a minimum of 85% of its
 portfolio in electric utilities. Investments in utilities are primarily in
 electric companies. Investments in non-utility stocks will not exceed 15% of
 the portfolio.
| |    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
| | 3. | Investment
 in speculative issues, including short sales, maximum of 15%.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

-6-

---



| |    |                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
| | -- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| | 4. | Limited use
 of options to increase yearly investment income.                                                                                                                             
| |    |                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
| |    | a.                                                                                                                                                                                         | The use of
 Call Options. Covered options can be sold up to a
 maximum of 20% of the value of the portfolio. This provides extra income in
 addition to dividends received from the companys investments. The risk of
 this strategy is that investments may be called away, which the company may
 have preferred to retain. Therefore, a limitation of 20% is placed on the amount
 of stock on which options can be written. The amount of the portfolio on
 which options are actually written is usually between 3-10% of the portfolio.
 The historical turnover of the portfolio is such that the average holding
 period is in excess of 5 years for available for sale securities.                                                                                                                                                                                                                                                                                                          
| |    |                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
| |    | b.                                                                                                                                                                                         | The use of
 Put options. Put options are written on stocks
 which the company is willing to purchase. While the company does not have a
 high rate of turnover in its portfolio, there is some turnover; for example,
 due to preferred stocks being called back by the issuing company, or stocks
 being called away because call options have been written. If the stock does
 not go below the put exercise price, the company records the proceeds from
 the sale as income. If the put is exercised, the cost basis is reduced by the
 proceeds received from the sale of the put option. There may be occasions
 where the cost basis of the stock is lower than the market price at the time
 the option is exercised.                                                                                                                                                                                                                                                                         
| |    |                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
| |    | c.                                                                                                                                                                                         | Speculative
 Short Sales/Short Options. The company normally
 limits its speculative transactions to no more than 15% of the value of the
 portfolio. The company may sell uncovered calls on certain stocks. If the
 stock price does not rise to the price of the call, the option is not
 exercised and the company records the proceeds from the sale of the call as
 income. If the call is exercised, the company will have a short position in
 the related stock. The company then has the choice of covering the short
 position, or selling a put against it. If the put is exercised, then the
 short position is covered. The companys current accounting policy is to mark
 to the market at the end of each quarter any short positions, and include it
 in the income statement. While the company may have so-called speculative
 positions equal to 15% of its accounts, in actual practice the short stock
 positions usually account for less than 10% of the assets of the company.
| |    |                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
| | 5. | In the event
 of a merger, the Company will elect to receive shares in the new company. In
 the event of a cash only offer, the Company will receive cash and be forced
 to sell it stock.

The
income derived from these investments has been essential to help offset the
research, operating and marketing expenses of developing the Blood Volume
Analyzer. The Company has followed a conservative policy of assuring adequate
liquidity so that it can expand its marketing and research and development
without the sudden necessity of raising additional capital. The securities in
the Companys portfolio are selected to provide stability of both income and
capital. The Company has been able to achieve financial stability because of
these returns, which have covered a significant portion of the Companys
continuing losses from operations. The Companys investment policy is reviewed
at least once yearly by the Board of Directors and the Audit Committee.
Individual investment decisions are made solely by Dr. Joseph Feldschuh, CEO,
who devotes approximately 8 to 10 hours per week to this activity. He is
assisted by a single part-time employee. No other member of the Company is
involved in individual investment decisions.

Revenue Recognition

The
Company recognizes operational revenues from several sources. The first source
is the outright sale of equipment, the Blood Volume Analyzer, to customers. The
second source is the sale and associated shipping revenues of single-use
radioactive doses (Volumex) that are injected into the patient and measured by
the Blood Volume Analyzer. The third source of revenue is service contracts on
the Blood Volume Analyzer, after it has been sold to a customer. The fourth
source of revenue is the storage fees associated with cryobanked blood and
semen specimens. The fifth is lab revenues from laboratory services, and the
sixth is revenue from semen sales.

-7-

---



The
Company currently offers three different methods of purchasing the Blood Volume
Analyzer equipment. A customer may purchase the equipment directly, lease the
equipment, or rent the equipment on a month-to-month basis. The revenues
generated by a direct sale or a monthly rental are recognized as revenue in the
period in which the sale or rental occurred. If a customer is to select the
lease option, the Company refers its customer to a third party finance
company with which it has established a relationship, and if the lease is
approved, the Company receives 100% of the sales proceeds from the finance
company and recognizes 100% of the revenue. The finance company then deals directly
with the customer with regard to lease payments and related collections.

The
sales of the single-use radioactive doses (Volumex) that are used in
conjunction with the Blood Volume Analyzer are recognized as revenue in the
period in which the sale occurred.

When
Blood Volume Analyzer equipment has been sold to a customer, the Company offers
a one year warranty on the product, which covers all mechanical failures. This
one year warranty is effective on the date of sale of the equipment. After the
one year period expires, customers may purchase a service contract through the
Company, which is usually offered in one-year, three year or five year
increments. These service contracts are billed quarterly and therefore the
revenue is earned in the quarter invoiced.

The
storage fees associated with the cryobanked blood and semen samples are
recognized as income in the period for which the fee applies. Although the
Company historically offered annual storage fee contracts, effective October 1,
2005, the Company only offers storage term contracts of three months or less.

Comprehensive Income (Loss)

The
Company reports components of comprehensive income under the requirements of
SFAS No. 130 - Reporting Comprehensive
Income. This statement establishes rules for the reporting of
comprehensive income and requires certain transactions to be presented as
separate components of stockholders equity. The Company currently reports the
unrealized holding gains and losses on available-for-sale securities, net of
deferred taxes, as accumulated other comprehensive income (loss).

Product Warrantees and Related Liabilities

The
Company offers a one year warranty on the Blood Volume Analyzer equipment. This
warranty is effective on the date of sale and covers all mechanical failures of
the equipment. All major components of the equipment are purchased and
warranted by the original third party manufacturers.

Once
the initial one year warranty period has expired, customers may purchase annual
service contracts for the equipment. These service contracts warranty the
mechanical failures of the equipment that are not associated with normal
wear-and-tear of the components.

To
date, the Company has not experienced any major mechanical failures on any
equipment sold. In addition, the majority of the potential liability would
revert to the original manufacturer. Due to this favorable history, a liability
has not been recorded with respect to product warranty liability.

Income Taxes

The
Company accounts for income taxes under the provisions of SFAS No. 109 -
Accounting for Income Taxes. This pronouncement requires recognition of
deferred tax assets and liabilities for the estimated future tax consequences
of events attributable to differences between the financial statement carrying
amounts of existing assets and liabilities and their respective tax bases and
operating loss and tax credit carry forwards. Deferred tax assets and
liabilities are measured using enacted tax rates in effect for the year in
which the differences are expected to be recovered or settled. The effect on
deferred tax assets and liabilities of changes in tax rates is recognized in
the statement of operations in the period in which the enactment rate changes.
Deferred tax assets and liabilities are reduced through the establishment of a
valuation allowance at such time as, based on available evidence, it is more
likely than not that the deferred tax assets will not be realized.

-8-

---



Item 3. Quantitative and Qualitative Disclosures About Market
Risk

The Securities
and Exchange Commissions rule related to market risk disclosure requires that
we describe and quantify our potential losses from market risk sensitive
instruments attributable to reasonably possible market changes. Market risk
sensitive instruments include all financial or commodity instruments and other
financial instruments that are sensitive to future changes in interest rates,
currency exchange rates, commodity prices or other market factors.

We are not
exposed to market risks from changes in foreign currency rates. The company
maintains an investment portfolio primarily consisting of electric utility
companies which are publicly traded common and preferred stock. These are
categorized as available-for-sale securities.

In addition to
receiving income from dividends, the company also has an investment policy of
selling puts on stocks that it is willing to own. Such options usually have a
maturity of less than 1 year. The company will also sell covered calls on
securities within its investment portfolio. Covered calls involve stocks, which
usually do not exceed 15% of the value of the companys portfolio and have
never exceeded 15% of the companys portfolio value.

The company
will, at times, sell naked or uncovered calls, as well as, engage in short
sales as part of a strategy to mitigate risk. Such short sales are usually less
than 15% of the companys portfolio value.

Puts, calls
and short sales, collectively referred to as short positions, are all marked to
market for each reporting period and any gain or loss is recognized through the
Statement of Operations and labeled as Mark to market of short positions.

The companys
investment strategy is reviewed at least once a year, and more frequently as
needed, at board meetings. The companys investing policy permits investment in
non-electric utilities for up to 15% of the corporate portfolio value.

At March 31,
2008, unrealized gains were $40,409,649 and unrealized losses were ($6,542,492)
on available for sale securities for a ratio of 6 to 1.

Certain
utility preferred stocks have call provisions which may enable them to be
called away from the company. The call price, in all instances, is higher than
the companys cost for the stock. The yields on such preferred stocks may be
significantly higher than current available yields. Such stocks, therefore,
could not be replaced with similar yields. At March 31, 2008, 3.54% of the
market value of the companys available for sale securities is made up of
preferred stock.

At March 31,
2008, 96.42% of the market value of the companys available for sale securities
is made up of common stock. There is a risk that any of these stocks could be
sold as the result of an involuntary tender offer and that the security could
not be replaced with an investment offering a similar yield.

The companys
portfolio value is exposed to fluctuations in the general value of electric
utilities. An increase of interest rates could affect the company in two ways;
one would be to put downward pressure on the valuation of utility stocks as
well as increase the companys cost of borrowing.

Because of the size of the
unrealized gains in the companys portfolio, the company does not anticipate
any changes which could reduce the value of the companys utility portfolio
below historical cost. Electric utilities operate in an environment of federal,
state and local regulations, and they may disproportionately affect an
individual utility. The companys exposure to regulatory risk is mitigated due
to the diversity of holdings consisting of 72 separate stocks. As of March 31,
2008 there were four holdings of common stock which comprise 53.76% of the
total market value of the available for sale investments.

-9-

---



DAXOR CORPORATION 
SUMMARY OF INVESTMENTS 
AS AT MARCH 31, 2008

|                       |  |      |            |                     |   |                                    |  |   |            |  
|---------------------- |  | ---- | ---------- | ------------------- | - | ---------------------------------- |  | - | ---------- | -
|                       |  | COST |            | FAIR
 MARKET
 VALUE |   | TOTAL NET
 UNREALIZED
 GAIN (LOSS) | 
|                       |  |      |            |                     |   |                                    | 
|TOTAL COMMON
 STOCK    |  | $    | 33,308,710 |                     | $ | 67,105,402                         |  | $ | 33,796,692 |  
|TOTAL
 PREFERRED STOCK |  |      | 2,358,400  |                     |   | 2,463,834                          |  |   | 105,434    |  
|                       |  |      |            |                     |   |                                    |  |   |            |  
|TOTAL
 EQUITIES        |  |      | 35,667,110 |                     |   | 69,569,236                         |  |   | 33,902,126 |  
|                       |  |      |            |                     |   |                                    |  |   |            |  
|TOTAL BONDS            |  |      | 65,770     |                     |   | 30,800                             |  |   | (34,970    | )
|                       |  |      |            |                     |   |                                    |  |   |            |  
|TOTAL
 PORTFOLIO       |  | $    | 35,732,880 |                     | $ | 69,600,036                         |  | $ | 33,867,156 |  
|                       |  |      |            |                     |   |                                    |  |   |            |  

DAXOR CORPORATION 
SUMMARY OF INVESTMENTS 
AS AT MARCH 31, 2007

|                       |  |      |            |                     |   |                                     |  |   |            | 
|---------------------- |  | ---- | ---------- | ------------------- | - | ----------------------------------- |  | - | ---------- | 
|                       |  | COST |            | FAIR
 MARKET
 VALUE |   | TOTAL
 NET
 UNREALIZED
 GAIN (LOSS) | 
|                       |  |      |            |                     |   |                                     | 
|TOTAL COMMON
 STOCK    |  | $    | 22,171,307 |                     | $ | 69,636,139                          |  | $ | 47,464,832 | 
|TOTAL
 PREFERRED STOCK |  |      | 832,418    |                     |   | 1,172,990                           |  |   | 340,572    | 
|                       |  |      |            |                     |   |                                     |  |   |            | 
|TOTAL
 EQUITIES        |  |      | 23,003,725 |                     |   | 70,809,129                          |  |   | 47,805,404 | 
|                       |  |      |            |                     |   |                                     |  |   |            | 
|TOTAL BONDS            |  |      | 184,646    |                     |   | 346,265                             |  |   | 161,619    | 
|                       |  |      |            |                     |   |                                     |  |   |            | 
|TOTAL
 PORTFOLIO       |  | $    | 23,188,371 |                     | $ | 71,155,394                          |  | $ | 47,967,023 | 
|                       |  |      |            |                     |   |                                     |  |   |            | 

Summary of
Proceeds Received and Market Valuation at 03/31/08 
Put and Call Options

|                                                         |  |                                        |           |                                                                  |   |                                                    |  |                            |           |                                                       |   |           |  |   |           | 
|-------------------------------------------------------- |  | -------------------------------------- | --------- | ---------------------------------------------------------------- | - | -------------------------------------------------- |  | -------------------------- | --------- | ----------------------------------------------------- | - | --------- |  | - | --------- | 
|Total Proceeds
 Received on
 open positions
 at 01/01/08 |  | Sale ofOptions from
 01/01/08-03/31/08 |           | Expirations and
 Assignments of
 Options from
 01/01/08-03/31/08 |   | Proceeds
 Received on
 open positions
 at 03/31/08 |  | Market
 Value at
 03/31/08 |           | Unrealized
 Appreciation
 (Depreciation)
 at 03/31/08 |  
|                                                         |  |                                        |           |                                                                  |   |                                                    |  |                            |           |                                                       |  
|$ 7,645,833                                              |  | $                                      | 8,434,122 |                                                                  | $ | 6,266,742                                          |  | $                          | 9,813,213 |                                                       | $ | 7,685,008 |  | $ | 2,128,205 | 

-10-

---



Summary of Proceeds Received and Market Valuation at 03/31/07Put and Call Options

|                                                         |  |                                        |           |                                                                  |   |                                                    |  |                            |           |                                                       |   |           |  |   |           | 
|-------------------------------------------------------- |  | -------------------------------------- | --------- | ---------------------------------------------------------------- | - | -------------------------------------------------- |  | -------------------------- | --------- | ----------------------------------------------------- | - | --------- |  | - | --------- | 
|Total Proceeds
 Received on
 open positions
 at 01/01/07 |  | Sale ofOptions from
 01/01/07-03/31/07 |           | Expirations and
 Assignments of
 Options from
 01/01/07-03/31/07 |   | Proceeds
 Received on
 open positions
 at 03/31/07 |  | Market
 Value at
 03/31/07 |           | Unrealized
 Appreciation
 (Depreciation)
 at 03/31/07 |  
|                                                         |  |                                        |           |                                                                  |   |                                                    |  |                            |           |                                                       |  
|$ 2,846,667                                              |  | $                                      | 3,096,982 |                                                                  | $ | 2,659,924                                          |  | $                          | 3,285,725 |                                                       | $ | 2,178,802 |  | $ | 1,106,923 | 

Item 4. Controls and Procedures

As of March
31, 2008, the Company carried out an evaluation, under the supervision and with
the participation of the Companys management, including the Companys Chief
Executive Officer, Chief Financial Officer and Treasurer, of the effectiveness
of the design and operation of the Companys disclosure controls and procedures
pursuant to Rule 13a-14 under the Securities and Exchange of 1934, as amended.

The Companys
management and board of directors are fully committed to the review and
evaluation of the procedures and policies designed to assure effective internal
control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

There
have been no material changes from the risk factors disclosed in the Companys
Annual Report on Form 10-K for the fiscal year ended December 31, 2007 as filed
with the Securities and Exchange Commission on March 31, 2008. A change in
Medicare and Medicaid reimbursement rates was effective as of January 1, 2008
and at this time the Company is unable to quantify the effect this change will
have on operating revenue. This change is discussed in greater detail in the
Recent Developments section of this 10-Q.

Item 2. Unregistered Sales of Equity
Securities and Use of Proceeds

None.

Item 3. Defaults upon Senior Securities

None.

Item 4. Submission of Matters to a Vote of
Security Holders

None.

Item 5. Other Information

None.

-11-

---



Item 6. Exhibits and Reports on Form 8-K

(a)
Exhibits

|     |  |                                                                                                                                                        
|---- |  | -------------------------------------------------------------------------------------------------------------------------------------------------------
|31.1 |  | Certification
 of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act
 of 2002                                                   
|     |  |                                                                                                                                                        
|31.2 |  | Certification
 of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley
 Act of 2002                                               
|     |  |                                                                                                                                                        
|32.1 |  | Certification
 of Chief Executive Officer pursuant to 18 U.S.C Section 1350, as adopted
 pursuant to Section 906 of the Sarbanes-Oxley Act of 2002     
|     |  |                                                                                                                                                        
|32.2 |  | Certification
 of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted
 pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(c)
There were no reports on Form 8-k filed.

-12-

---



SIGNATURES

| |                                                                                                                                                                                                                      
| | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| | Pursuant to
 the requirements of Section 13 or 15(d)of the Securities and Exchange Act of
 1934,the registrant has duly caused this report to be signed on its behalf by
 the undersigned, thereunto duly authorized.

|                    |     |                                       
|------------------- | --- | --------------------------------------
|DATE: May
 15, 2008 | By: | /s/ JOSEPH
 FELDSCHUH, M.D.           
|                    |     |                                       
|                    |     | JOSEPH
 FELDSCHUH, M.D.,              
|                    |     | President
 and Chief Executive Officer
|                    |     |                                       
|                    |     |                                       
|DATE: May
 15, 2008 | By: | /s/ DAVID
 FRANKEL                    
|                    |     |                                       
|                    |     | DAVID
 FRANKEL                        
|                    |     | Chief
 Financial Officer              

-13-

---